| 1 |
Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, Wu JY, Kuo CH, Huang YK, Wu DC. Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol 2015; 21(40): 11221-11235 [PMID: 26523098 DOI: 10.3748/wjg.v21.i40.11221] [Cited by in CrossRef: 131] [Cited by in F6Publishing: 114] [Article Influence: 18.7] [Reference Citation Analysis]
|
| 2 |
. UEG Week 2016 Oral Presentations. United European Gastroenterology Journal 2016;4:A1-A156. [DOI: 10.1177/2050640616663688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 3 |
Chey WD, Howden CW, Leontiadis GI. Clarifying the Houston Consensus on Helicobacter pylori. Clin Gastroenterol Hepatol 2018;16:2003-4. [PMID: 30454936 DOI: 10.1016/j.cgh.2018.07.024] [Reference Citation Analysis]
|
| 4 |
Binh TT, Shiota S, Suzuki R, Matsuda M, Trang TT, Kwon DH, Iwatani S, Yamaoka Y. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother. 2014;69:1796-1803. [PMID: 24648504 DOI: 10.1093/jac/dku050] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 5 |
Ji R, Li YQ, Gu XM, Yu T, Zuo XL, Zhou CJ. Confocal laser endomicroscopy for diagnosis of Helicobacter pylori infection: a prospective study. J Gastroenterol Hepatol. 2010;25:700-705. [PMID: 20492325 DOI: 10.1111/j.1440-1746.2009.06197.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 6 |
Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter. 2012;17:43-48. [PMID: 22221615 DOI: 10.1111/j.1523-5378.2011.00896.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 7 |
Rizwan M, Fatima N, Alvi A. Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: scenario from Saudi Arabia. Saudi J Gastroenterol 2014;20:212-8. [PMID: 25038206 DOI: 10.4103/1319-3767.136935] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 8 |
Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost 2018;16:1656-64. [DOI: 10.1111/jth.14192] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 9 |
Huh CW, Kim B. Diagnosis of Helicobacter pylori Infection. Korean J Gastroenterol 2018;72:229. [DOI: 10.4166/kjg.2018.72.5.229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Suzuki J, Shimazaki K, Koike S, Ono T. Gastric emptying rate before and after orthodontic treatment examined with the [13C] breath test: A pilot study. Am J Orthod Dentofacial Orthop 2018;153:347-54. [PMID: 29501109 DOI: 10.1016/j.ajodo.2017.06.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Kawashima J, Matsubara Y, Miwa J, Yakabi K. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol 2012;47:276-83. [DOI: 10.1007/s00535-011-0487-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 12 |
Sabbagh P, Mohammadnia-afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, Nouri HR, Ebrahimpour S. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J Clin Microbiol Infect Dis 2019;38:55-66. [DOI: 10.1007/s10096-018-3414-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 13 |
Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 14 |
Kamboj AK, Cotter TG, Oxentenko AS. Helicobacter pylori. Mayo Clinic Proceedings 2017;92:599-604. [DOI: 10.1016/j.mayocp.2016.11.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 15 |
Otto M, Ronellenfitsch U, Tröndle S, Kienle P, Kähler G, Hasenberg T. Is Preoperative Esophagoduodenoscopy Required in all Patients Prior to Bariatric Surgery? Bariatric Surgical Practice and Patient Care 2015;10:160-4. [DOI: 10.1089/bari.2015.0024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 16 |
Thirumurthi S, Desilva R, Castillo DL, Richardson P, Abraham NS. Identification of Helicobacter pylori infected patients, using administrative data. Alimentary Pharmacology & Therapeutics 2008;28:1309-16. [DOI: 10.1111/j.1365-2036.2008.03845.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20(30): 10338-10347 [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 18 |
Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73. [PMID: 19755966 DOI: 10.1038/ajg.2009.508] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 19 |
Patel KA, Howden CW. Update on the Diagnosis and Management of Helicobacter pylori Infection in Adults. J Clin Gastroenterol. 2015;49:461-467. [PMID: 25811119 DOI: 10.1097/MCG.0000000000000318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 20 |
Jonaitis L, Kiudelis G, Slepavicius P, Kupcinskas L. High rate of Helicobacter pylori reinfection in Lithuanian peptic ulcer patients. World J Gastrointest Pathophysiol 2016; 7(1): 181-185 [PMID: 26909241 DOI: 10.4291/wjgp.v7.i1.181] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 21 |
de Korwin JD. [New recommendations for the diagnosis and the treatment of Helicobacter pylori infection]. Presse Med. 2013;42:309-317. [PMID: 23021657 DOI: 10.1016/j.lpm.2012.07.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 22 |
Wee EW. Evidence-based approach to dyspepsia: from Helicobacter pylori to functional disease. Postgrad Med 2013;125:169-80. [PMID: 23933904 DOI: 10.3810/pgm.2013.07.2688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 23 |
Minkara MS, Ucisik MN, Weaver MN, Merz KM Jr. Molecular Dynamics Study of Helicobacter pylori Urease. J Chem Theory Comput 2014;10:1852-62. [PMID: 24839409 DOI: 10.1021/ct5000023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 24 |
Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016;16:256. [PMID: 27809767 DOI: 10.1186/s12866-016-0873-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 25 |
Tatemichi M, Sasazuki S, Inoue M, Tsugane S; JPHC Study Group. Clinical significance of IgG antibody titer against Helicobacter pylori. Helicobacter. 2009;14:231-236. [PMID: 19702853 DOI: 10.1111/j.1523-5378.2009.00681.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 26 |
Shuto M, Fujioka T, Matsunari O, Okamoto K, Mizukami K, Okimoto T, Kodama M, Takigami S, Seguchi C, Nonaka Y, Sato R, Yamaoka Y, Murakami K. Association between Gastric Cancer Risk and Serum Helicobacter pylori Antibody Titers. Gastroenterol Res Pract 2017;2017:1286198. [PMID: 28690637 DOI: 10.1155/2017/1286198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 27 |
Huerta-Franco MR, Banderas JW, Allsworth JE. Ethnic/racial differences in gastrointestinal symptoms and diagnosis associated with the risk of Helicobacter pylori infection in the US. Clin Exp Gastroenterol 2018;11:39-49. [PMID: 29403299 DOI: 10.2147/CEG.S144967] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 28 |
Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol. 2013;47:228-232. [PMID: 22858517 DOI: 10.1097/mcg.0b013e31826015b0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 29 |
Pan X, Li Y, Qiu Y, Tang Q, Qian B, Yao L, Shi R, Zhang G. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in chinese adults. Clinical Therapeutics 2010;32:2003-11. [DOI: 10.1016/j.clinthera.2010.11.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 30 |
Rayner CK, Talley NJ, Horowitz M. Stomach bugs and diabetes: an astounding observation or just confounding? Diabetes Care 2012;35:463-4. [PMID: 22355017 DOI: 10.2337/dc11-2470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 31 |
Tarkhashvili N, Chakvetadze N, Mebonia N, Chubinidze M, Bakanidze L, Shengelidze V, Mirtskhulava M, Chachava T, Katsitadze G, Gabunia U, Kordzaia D, Imnadze P, Guarner J, Sobel J. Traditional risk factors for Helicobacter pylori infection not found among patients undergoing diagnostic upper endoscopy-Republic of Georgia, 2007-2008. Int J Infect Dis 2012;16:e697-702. [PMID: 22867956 DOI: 10.1016/j.ijid.2012.05.1031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 32 |
Moretti E, Figura N, Campagna MS, Gonnelli S, Iacoponi F, Collodel G. Sperm Parameters and Semen Levels of Inflammatory Cytokines in Helicobacter pylori–infected Men. Urology 2015;86:41-7. [DOI: 10.1016/j.urology.2015.02.068] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 33 |
El-Zimaity H, Serra S, Szentgyorgyi E, Vajpeyi R, Samani A. Gastric biopsies: the gap between evidence-based medicine and daily practice in the management of gastric Helicobacter pylori infection. Can J Gastroenterol 2013;27:e25-30. [PMID: 24106732 DOI: 10.1155/2013/897423] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 34 |
Miendje Deyi VY, Bontems P, Vanderpas J, De Koster E, Ntounda R, Van den Borre C, Cadranel S, Burette A. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol. 2011;49:2200-2209. [PMID: 21450969 DOI: 10.1128/jcm.02642-10] [Cited by in Crossref: 54] [Cited by in F6Publishing: 18] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 35 |
Gisbert JP, Calvet X, O’Connor A, Mégraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313-325. [PMID: 20054285 DOI: 10.1097/mcg.0b013e3181c8a1a3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 61] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 36 |
Bakheit AH, Al-Kahtani HM, Albraiki S. Rabeprazole: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol 2021;46:137-83. [PMID: 33461697 DOI: 10.1016/bs.podrm.2020.07.003] [Reference Citation Analysis]
|
| 37 |
Satpathi P, Satpathi S, Mohanty S, Mishra SK, Behera PK, Maity AB. Helicobacter pylori infection in dyspeptic patients in an industrial belt of India. Trop Doct 2017;47:2-6. [PMID: 26774110 DOI: 10.1177/0049475515626033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 38 |
Horikawa C, Kodama S, Fujihara K, Yachi Y, Tanaka S, Suzuki A, Hanyu O, Shimano H, Sone H. Association of Helicobacter pylori infection with glycemic control in patients with diabetes: a meta-analysis. J Diabetes Res. 2014;2014:250620. [PMID: 24901007 DOI: 10.1155/2014/250620] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 39 |
Grišin E, Mikalauskas S, Poškus T, Jotautas V, Strupas K. Laparoscopic pyloroplasty for perforated peptic ulcer. Wideochir Inne Tech Maloinwazyjne 2017;12:311-4. [PMID: 29062455 DOI: 10.5114/wiitm.2017.68537] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 40 |
Ozturk A. Periodontal Treatment Is Associated With Improvement in Gastric Helicobacter pylori Eradication: An Updated Meta-analysis of Clinical Trials. Int Dent J 2021;71:188-96. [PMID: 34024329 DOI: 10.1111/idj.12616] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 41 |
Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
|
| 42 |
Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol 2015; 21(21): 6698-6705 [PMID: 26074708 DOI: 10.3748/wjg.v21.i21.6698] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 43 |
Egan BJ, Marzio L, O’Connor H, O’Morain C. Treatment of Helicobacter pylori infection. Helicobacter. 2008;13 Suppl 1:35-40. [PMID: 18783520 DOI: 10.1111/j.1523-5378.2008.00639.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 44 |
Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, Piñeiro L, Recasens M, Ibarra B, Sarasqueta C, Bujanda L. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clinical Microbiology and Infection 2013;19:379-83. [DOI: 10.1111/j.1469-0691.2012.03844.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 45 |
Tang RS, Wu JC. Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole. Clin Interv Aging 2013;8:1433-43. [PMID: 24187492 DOI: 10.2147/CIA.S41350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 46 |
Zevit N, Levy I, Shmuely H, Samra Z, Yahav J. Antibiotic resistance of Helicobacter pylori in Israeli children. Scandinavian Journal of Gastroenterology 2010;45:550-5. [DOI: 10.3109/00365521003663688] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 47 |
Salimi A, Eybagi S, Seydi E, Naserzadeh P, Kazerouni NP, Pourahmad J. Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. Xenobiotica 2016;46:82-93. [PMID: 26068526 DOI: 10.3109/00498254.2015.1046975] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 48 |
Ginestet F, Guibourg B, Doucet L, Théreaux J, Robaszkiewicz M, Marcorelles P, Uguen A. Upfront immunohistochemistry improves specificity of Helicobacter pylori diagnosis. A French pathology laboratory point of view. Helicobacter 2017;22:e12424. [DOI: 10.1111/hel.12424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 49 |
Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104:3069-79; quiz 1080. [PMID: 19844205 DOI: 10.1038/ajg.2009.555] [Cited by in Crossref: 188] [Cited by in F6Publishing: 199] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 50 |
Gisbert JP, Calvet X, O'connor JA, Mégraud F, O'morain CA. The sequential therapy regimen for Helicobacter pylori eradication. Expert Opinion on Pharmacotherapy 2010;11:905-18. [DOI: 10.1517/14656561003657152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 51 |
Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015;9:707-716. [PMID: 25667617 DOI: 10.3892/etm.2015.2174] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 52 |
Noronha BP, Mambrini JVM, Torres KCL, Martins-Filho OA, Teixeira-Carvalho A, Lima-Costa MF, Peixoto SV. Chlamydia pneumoniae and Helicobacter pylori infections and immunological profile of community-dwelling older adults. Exp Gerontol 2021;156:111589. [PMID: 34637947 DOI: 10.1016/j.exger.2021.111589] [Reference Citation Analysis]
|
| 53 |
Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. Arab Journal of Gastroenterology 2017;18:62-7. [DOI: 10.1016/j.ajg.2017.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 54 |
Worden JC, Hanna KS. Optimizing proton pump inhibitor therapy for treatment of nonvariceal upper gastrointestinal bleeding. American Journal of Health-System Pharmacy 2017;74:109-16. [DOI: 10.2146/ajhp151032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 55 |
Xiang Z, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, Yang YD, Jin X. Helicobacter pylori and Crohn’s disease: A retrospective single-center study from China. World J Gastroenterol 2013; 19(28): 4576-4581 [PMID: 23901235 DOI: 10.3748/wjg.v19.i28.4576] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 56 |
Tajalli R, Nobakht M, Mohammadi-Barzelighi H, Agah S, Rastegar-Lari A, Sadeghipour A. The immunohistochemistry and toluidine blue roles for Helicobacter pylori detection in patients with gastritis. Iran Biomed J. 2013;17:36-41. [PMID: 23279833 DOI: 10.6091/ibj.1094.2012] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 57 |
Abdulqawi K, El-Mahalaway AM, Abdelhameed A, Abdelwahab AA. Correlation of serum antibody titres with invasive methods for rapid detection of Helicobacter pylori infections in symptomatic children. Int J Exp Pathol. 2012;93:295-304. [PMID: 22804766 DOI: 10.1111/j.1365-2613.2012.00831.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 58 |
Hinojosa WI, Quiróz MA, Álvarez IR, Castañeda PE, Villarreal ML, Taketa AC. Anti-Helicobacter pylori, gastroprotective, anti-inflammatory, and cytotoxic activities of methanolic extracts of five different populations of Hippocratea celastroides collected in Mexico. J Ethnopharmacol 2014;155:1156-63. [PMID: 24971795 DOI: 10.1016/j.jep.2014.06.044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 59 |
Frater JL. The Top 100 Cited Papers in the Field of Iron Deficiency in Humans: A Bibliometric Study. Biomed Res Int 2021;2021:5573790. [PMID: 34235219 DOI: 10.1155/2021/5573790] [Reference Citation Analysis]
|
| 60 |
Stathis A, Bertoni F, Zucca E. Treatment of gastric marginal zone lymphoma of MALT type. Expert Opin Pharmacother. 2010;11:2141-2152. [PMID: 20586708 DOI: 10.1517/14656566.2010.497141] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 61 |
Auesomwang C, Maneerattanaporn M, Chey WD, Kiratisin P, Leelakusolwong S, Tanwandee T. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2018;33:1822-1828. [PMID: 29804294 DOI: 10.1111/jgh.14292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 62 |
Rezaizadeh H, Olson E. Specific GI Microbial Infections. In: Wu GY, editor. Pocket Handbook of GI Pharmacotherapeutics. Cham: Springer International Publishing; 2016. pp. 75-109. [DOI: 10.1007/978-3-319-33317-5_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 63 |
Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105:493-498. [PMID: 20203636 DOI: 10.1038/ajg.2009.728] [Cited by in Crossref: 191] [Cited by in F6Publishing: 183] [Article Influence: 15.9] [Reference Citation Analysis]
|
| 64 |
Hagymási K, Tulassay Z. The new aspects of the eradication of Helicobacter pylori and the importance of bacterial resistance. Orvosi Hetilap 2008;149:2029-35. [DOI: 10.1556/oh.2008.28460] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 65 |
Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008; 14(39): 6065-6071 [PMID: 18932287 DOI: 10.3748/wjg.14.6065] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 66 |
Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett. 2015;359:345-351. [PMID: 25853150 DOI: 10.1016/j.canlet.2015.01.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 67 |
McMahon BJ, Bruce MG, Koch A, Goodman KJ, Tsukanov V, Mulvad G, Borresen ML, Sacco F, Barrett D, Westby S, Parkinson AJ. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiol Infect 2016;144:225-33. [PMID: 26094936 DOI: 10.1017/S0950268815001181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 68 |
Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23:e880-e893. [PMID: 25569598 DOI: 10.1097/mjt.0000000000000191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 69 |
Tankovic J, Delchier J. Données actuelles sur la prise en charge de l’infection par Helicobacter pylori. Antibiotiques 2010;12:137-44. [DOI: 10.1016/j.antib.2010.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 70 |
Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol. 2009;7:145-148. [PMID: 19026766 DOI: 10.1016/j.cgh.2008.10.024] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 71 |
Selvaratnam S, Yeoh J, Hsiang J, Patrick AB. A win for the patient: Direct patient notification improves treatment rates of active Helicobacter pylori infection. Australas Med J. 2014;7:350-354. [PMID: 25279011 DOI: 10.4066/amj.2014.2132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 72 |
Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, Song HJ, Jung HY, Kim JH. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol. 2012;27:493-497. [PMID: 21793912 DOI: 10.1111/j.1440-1746.2011.06874.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 73 |
Abd-Elsalam S, Kobtan A, El-Kalla F, Elkhalawany W, Nawasany SE, Saif SA, Yousef M, Ali LA, Soliman S, Mansour L, Habba E, Soliman H, Rizk F, Shehata MA. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 2016;95:e3879. [PMID: 27310977 DOI: 10.1097/MD.0000000000003879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 74 |
Rogers BB, Gold BD. Helicobacter pylori Gastritis: Susceptible to Further Testing? Dig Dis Sci 2016;61:2156-9. [PMID: 27234271 DOI: 10.1007/s10620-016-4200-8] [Reference Citation Analysis]
|
| 75 |
Zhang YY, Xia HH, Zhuang ZH, Zhong J. Review article: 'true' re-infection of Helicobacter pylori after successful eradication--worldwide annual rates, risk factors and clinical implications. Aliment Pharmacol Ther. 2009;29:145-160. [PMID: 18945250 DOI: 10.1111/j.1365-2036.2008.03873.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 76 |
Kim CG, Choi IJ, Lee JY, Cho S, Nam B, Kook M, Hong EK, Kim Y. Biopsy site for detecting Helicobacter pylori infection in patients with gastric cancer. Journal of Gastroenterology and Hepatology 2009;24:469-74. [DOI: 10.1111/j.1440-1746.2008.05679.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 77 |
Choi J, Kim CH, Kim D, Chung SJ, Song JH, Kang JM, Yang JI, Park MJ, Kim YS, Yim JY. Prospective evaluation of a new stool antigen test for the detection of Helicobacter pylori, in comparison with histology, rapid urease test, (13)C-urea breath test, and serology. J Gastroenterol Hepatol. 2011;26:1053-1059. [PMID: 21362044 DOI: 10.1111/j.1440-1746.2011.06705.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 78 |
So HM, Yu JS, Khan Z, Subedi L, Ko YJ, Lee IK, Park WS, Chung SJ, Ahn MJ, Kim SY, Kim KH. Chemical constituents of the root bark of Ulmus davidiana var. japonica and their potential biological activities. Bioorg Chem 2019;91:103145. [PMID: 31357073 DOI: 10.1016/j.bioorg.2019.103145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 79 |
Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR, Vaiphei K, Sathiyasekaran M, Sahu MK, Rout N, Abraham P, Dalai PC, Rathi P, Sinha SK, Bhatia S, Patra S, Ghoshal U, Poddar U, Mouli VP, Kate V. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol 2021. [PMID: 34219211 DOI: 10.1007/s12664-021-01186-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 80 |
Abdel-Moein KA, Saeed H, Samir A. Novel detection of Helicobacter pylori in fish: A possible public health concern. Acta Trop. 2015;152:141-144. [PMID: 26364719 DOI: 10.1016/j.actatropica.2015.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 81 |
Feder R, Posner S, Qin Y, Zheng J, Chow S, Garman KS. Helicobacter pylori ‐associated peptic ulcer disease: A retrospective analysis of post‐treatment testing practices. Helicobacter 2018;23. [DOI: 10.1111/hel.12540] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 82 |
Liu Q, Zhang Y, Xu C, Chen B, Xu H, Cao Y, Guo T, Gao Y, Zhou Z, Zhou X, Xu X, He J. Dentists Are at a Higher Risk for Oral Helicobacter pylori Infection. Biomed Res Int 2020;2020:3945189. [PMID: 32695813 DOI: 10.1155/2020/3945189] [Reference Citation Analysis]
|
| 83 |
Arama SS, Tiliscan C, Negoita C, Croitoru A, Arama V, Mihai CM, Pop F, Garg A. Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients. Gastroenterol Res Pract 2016;2016:5061640. [PMID: 26858750 DOI: 10.1155/2016/5061640] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 84 |
Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
|
| 85 |
Li B, Lan X, Wang L, Zhao J, Ding J, Ding H, Lei J, Wei Y, Zhang W. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microb Pathog 2020;142:104075. [PMID: 32074497 DOI: 10.1016/j.micpath.2020.104075] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 86 |
Ennkaa A, Shaath N, Salam A, Mohammad RM. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study. Turk J Gastroenterol 2018;29:549-54. [PMID: 30260776 DOI: 10.5152/tjg.2018.17707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 87 |
Lee M, Baek H, Park JS, Kim S, Kyung C, Baik SJ, Lee BK, Kim JH, Ahn CW, Kim KR, Kang S. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. PLoS One 2018;13:e0193646. [PMID: 29499055 DOI: 10.1371/journal.pone.0193646] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 88 |
Dorer MS, Talarico S, Salama NR. Helicobacter pylori's unconventional role in health and disease. PLoS Pathog 2009;5:e1000544. [PMID: 19855816 DOI: 10.1371/journal.ppat.1000544] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 89 |
Nkuize M, Vanderpas J, Buset M, Delforge M, Cadière GB, De Wit S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med 2021;22:547-56. [PMID: 33765332 DOI: 10.1111/hiv.13083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 90 |
Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014; 20(29): 9898-9911 [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 91 |
Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, Das R, Lu H, Lin JT, Tu YK. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707-715. [PMID: 28781119 DOI: 10.1016/s2468-1253(17)30219-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 39] [Article Influence: 19.2] [Reference Citation Analysis]
|
| 92 |
Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther. 2012;35:56-65. [PMID: 22066530 DOI: 10.1111/j.1365-2036.2011.04902.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 93 |
Minkara MS, Weaver MN, Merz KM. Effect of 10.5 M Aqueous Urea on Helicobacter pylori Urease: A Molecular Dynamics Study. Biochemistry 2015;54:4121-30. [DOI: 10.1021/acs.biochem.5b00078] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 94 |
Cao D, Jiang J, You L, Jia Z, Tsukamoto T, Cai H, Wang S, Hou Z, Suo YE, Cao X. The protective effects of 18β-glycyrrhetinic acid on Helicobacter pylori-infected gastric mucosa in Mongolian Gerbils. Biomed Res Int. 2016;2016:4943793. [PMID: 27006947 DOI: 10.1155/2016/4943793] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 95 |
Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter. 2009;14:77-85. [PMID: 19751431 DOI: 10.1111/j.1523-5378.2009.00709.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 96 |
Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. [PMID: 23926315 DOI: 10.1136/bmj.f4587] [Cited by in Crossref: 161] [Cited by in F6Publishing: 156] [Article Influence: 17.9] [Reference Citation Analysis]
|
| 97 |
Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter. 2020;25:e12685. [PMID: 32141173 DOI: 10.1111/hel.12685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 98 |
Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 2018;97:212-8. [PMID: 29393194 DOI: 10.1159/000485097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 99 |
Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. [PMID: 22457599 DOI: 10.2147/ceg.s25419] [Cited by in Crossref: 90] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 100 |
Harmon RC, Peura DA. Evaluation and management of dyspepsia. Therap Adv Gastroenterol. 2010;3:87-98. [PMID: 21180593 DOI: 10.1177/1756283x09356590] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 101 |
Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ; American College of Cardiology Foundation., American College of Gastroenterology., American Heart Association. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008;103:2890-907. [PMID: 18853965 DOI: 10.1111/j.1572-0241.2008.02216.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 78] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 102 |
Zihlif M, Bashaireh B, Rashid M, Almadani Z, Jarrar Y. Effect of major CYP2C19 genetic polymorphisms on Helicobacter pylori eradication based on different treatment regimens. Biomed Rep 2022;16:2. [PMID: 34820125 DOI: 10.3892/br.2021.1485] [Reference Citation Analysis]
|
| 103 |
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Prefer Adherence 2016;10:1025-35. [PMID: 27354772 DOI: 10.2147/PPA.S102760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 104 |
Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L, Soussy CJ, Delchier JC, Megraud F. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol. 2009;47:3600-3607. [PMID: 19759218 DOI: 10.1128/jcm.00744-09] [Cited by in Crossref: 93] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 105 |
Nontakham J, Charoenram N, Upamai W, Taweechotipatr M, Suksamrarn S. Anti-Helicobacter pylori xanthones of Garcinia fusca. Arch Pharm Res 2014;37:972-7. [DOI: 10.1007/s12272-013-0266-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 106 |
Siddiqui I, Ahmed S, Abid S. Update on diagnostic value of breath test in gastrointestinal and liver diseases. World J Gastrointest Pathophysiol 2016; 7(3): 256-265 [PMID: 27574563 DOI: 10.4291/wjgp.v7.i3.256] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 107 |
Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study. Helicobacter. 2012;17:374-381. [PMID: 22967121 DOI: 10.1111/j.1523-5378.2012.00960.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 108 |
Harb AH, El Reda ZD, Sarkis FS, Chaar HF, Sharara AI. Efficacy of reduced-dose regimen of a capsule containing bismuth subcitrate, metronidazole, and tetracycline given with amoxicillin and esomeprazole in the treatment of Helicobacter Pylori infection. United European Gastroenterol J 2015;3:95-6. [PMID: 25653863 DOI: 10.1177/2050640614560787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 109 |
Dede F, Civen H, Dane F, Aliustaoglu M, Turhal S, Turoglu HT, Inanir S. Carbon-14 urea breath test: does it work in patients with partial gastric resection? Ann Nucl Med 2015;29:786-91. [DOI: 10.1007/s12149-015-1005-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 110 |
Barton JC, Wiener HH, Acton RT, Adams PC, Eckfeldt JH, Gordeuk VR, Harris EL, McLaren CE, Harrison H, McLaren GD, Reboussin DM. Prevalence of iron deficiency in 62,685 women of seven race/ethnicity groups: The HEIRS Study. PLoS One 2020;15:e0232125. [PMID: 32324809 DOI: 10.1371/journal.pone.0232125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 111 |
Yoon H, Lee DH, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. Gut Liver 2016;10:520-5. [PMID: 26347514 DOI: 10.5009/gnl15048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 112 |
Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274-279. [PMID: 23418857 DOI: 10.1111/hel.12046] [Cited by in Crossref: 96] [Cited by in F6Publishing: 97] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 113 |
Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121-128.e1. [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050] [Cited by in Crossref: 128] [Cited by in F6Publishing: 118] [Article Influence: 14.2] [Reference Citation Analysis]
|
| 114 |
Masjedizadeh A, Zaeemzadeh N, Mard SA, Vanani GS. Comparing the efficacy of four different protocols for eradicating of Helicobacter pylori infection in Ahvaz, southwest Iran. Prz Gastroenterol. 2015;10:94-99. [PMID: 26557940 DOI: 10.5114/pg.2015.49001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 115 |
Lee JY, Kim N. [Future trends of Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol. 2014;63:158-170. [PMID: 24651589 DOI: 10.4166/kjg.2014.63.3.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 116 |
Kuo SH, Yeh KH, Wu MS, Lin CW, Hsu PN, Wang HP, Chen LT, Cheng AL. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119:4838-4844; quiz 5057. [PMID: 22403257 DOI: 10.1182/blood-2012-01-404194] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 117 |
Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Reference Citation Analysis]
|
| 118 |
Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gomez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP; European Registry on H. pylori management (Hp‐EuReg). Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581-9. [PMID: 25776067 DOI: 10.1111/apt.13069] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 119 |
Wong A, Ching SS, Long AS. The use of a second biopsy from the gastric body for the detection of Helicobacter pylori using rapid urease test. Singapore Med J. 2014;55:644-647. [PMID: 25630318 DOI: 10.11622/smedj.2014178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 120 |
Dohi O, Yagi N, Onozawa Y, Kimura-Tsuchiya R, Majima A, Kitaichi T, Horii Y, Suzuki K, Tomie A, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Linked color imaging improves endoscopic diagnosis of active Helicobacter pylori infection. Endosc Int Open. 2016;4:E800-E805. [PMID: 27556101 DOI: 10.1055/s-0042-109049] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 121 |
Noya H, Anat B, Moshe L, Gennady P, Zamir H, Menachem M. Do urea breath test (UBT) referrals for Helicobacter pylori testing match the clinical guidelines in primary care practice? A prospective observational study: Breath test referrals. Journal of Evaluation in Clinical Practice 2008;14:799-802. [DOI: 10.1111/j.1365-2753.2008.01039.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 122 |
Moshiree B, Barboza J, Talley N. An update on current pharmacotherapy options for dyspepsia. Expert Opinion on Pharmacotherapy 2013;14:1737-53. [DOI: 10.1517/14656566.2013.809063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 123 |
Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109:485-495. [PMID: 24589670 DOI: 10.1038/ajg.2014.24] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 124 |
McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014;63:244-249. [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 125 |
Bjorkman DJ, Steenblik M. Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol 2017;15:648-59. [PMID: 28932965 DOI: 10.1007/s11938-017-0157-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 126 |
Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, Akyıldız E, Topbaş M, Özgür O, Arslan M. Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol 2020;31:221-33. [PMID: 32343234 DOI: 10.5152/tjg.2020.18631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 127 |
Qi Q, Guo C, Ji R, Li Z, Zuo X, Li Y. Diagnostic Performance of Magnifying Endoscopy for Helicobacter pylori Infection: A Meta-Analysis. PLoS One. 2016;11:e0168201. [PMID: 27992489 DOI: 10.1371/journal.pone.0168201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 128 |
Qaria MA, Qumar S, Sepe LP, Ahmed N. Cholesterol glucosylation-based survival strategy in Helicobacter pylori. Helicobacter 2021;26:e12777. [PMID: 33368895 DOI: 10.1111/hel.12777] [Reference Citation Analysis]
|
| 129 |
Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter. 2017;22. [PMID: 28066960 DOI: 10.1111/hel.12368] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 130 |
Rakici H, Akdoğan RA, Bedir R, Copur A, Yilmaz A. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. J Dig Dis 2014;15:508-13. [PMID: 24980811 DOI: 10.1111/1751-2980.12171] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 131 |
Khalil MA, El-Sheekh MM, El-Adawi HI, El-Deeb NM, Hussein MZ. Efficacy of microencapsulated lactic acid bacteria in Helicobater pylori eradication therapy. J Res Med Sci. 2015;20:950-957. [PMID: 26929759 DOI: 10.4103/1735-1995.172782] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 132 |
Miftahussurur M, Yamaoka Y. Diagnostic Methods of Helicobacter pylori Infection for Epidemiological Studies: Critical Importance of Indirect Test Validation. Biomed Res Int 2016;2016:4819423. [PMID: 26904678 DOI: 10.1155/2016/4819423] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 133 |
Zullo A, Hassan C, Andriani A, Cristofari F, Bassanelli C, Spinelli GP, Tomao S, Morini S. Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis. Med Oncol. 2010;27:291-295. [PMID: 19308737 DOI: 10.1007/s12032-009-9207-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 134 |
Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30:1338-1345. [PMID: 25867718 DOI: 10.1111/jgh.12984] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 135 |
Park JY, Forman D, Greenberg ER, Herrero R. Helicobacter pylori eradication in the prevention of gastric cancer: are more trials needed? Curr Oncol Rep. 2013;15:517-525. [PMID: 24101366 DOI: 10.1007/s11912-013-0341-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 136 |
Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011;16:146-152. [PMID: 21435093 DOI: 10.1111/j.1523-5378.2011.00829.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 137 |
Yin SM, Zhang F, Shi DM, Xiang P, Xiao L, Huang YQ, Zhang GS, Bao ZJ. Effect of posture on 13C-urea breath test in partial gastrectomy patients. World J Gastroenterol 2015; 21(45): 12888-12895 [PMID: 26668514 DOI: 10.3748/wjg.v21.i45.12888] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 138 |
Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 139 |
Campanati A, Ganzetti G, Martina E, Giannoni M, Gesuita R, Bendia E, Giuliodori K, Sandroni L, Offidani A. Helicobacter pylori infection in psoriasis: results of a clinical study and review of the literature. Int J Dermatol. 2015;54:e109-e114. [PMID: 25808243 DOI: 10.1111/ijd.12798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 140 |
Schmitt BH, Regner M, Mangold KA, Thomson RB, Kaul KL. PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. Mod Pathol. 2013;26:1222-1227. [PMID: 23579617 DOI: 10.1038/modpathol.2013.48] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 141 |
Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I, Malli A, Sharara AI. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2011;23:865-870. [PMID: 21811161 DOI: 10.1097/meg.0b013e3283496502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 142 |
Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter. 2017;22. [PMID: 28425141 DOI: 10.1111/hel.12389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 143 |
Yazdanbod A, Salimian S, Habibzadeh S, Hooshyar A, Maleki N, Norouzvand M. Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. Arch Med Sci. 2015;11:964-969. [PMID: 26528337 DOI: 10.5114/aoms.2015.54851] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
|
| 144 |
Milani M, Ghotaslou R, Akhi MT, Nahaei MR, Hasani A, Somi MH, Rafeey M, Sharifi Y. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother. 2012;18:848-852. [PMID: 22581031 DOI: 10.1007/s10156-012-0425-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 145 |
Sung JK. Diagnosis and management of gastric dysplasia. Korean J Intern Med 2016;31:201-9. [PMID: 26932397 DOI: 10.3904/kjim.2016.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 146 |
Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am 2016;100:827-50. [PMID: 27235617 DOI: 10.1016/j.mcna.2016.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 147 |
Yang JC, Lee PI, Hsueh PR. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007. Eur J Clin Microbiol Infect Dis. 2010;29:1369-1375. [PMID: 20658256 DOI: 10.1007/s10096-010-1009-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 148 |
Kumral TL, Gökden Y, Saltürk Z, Berkiten G, Yıldırım G, Ataç E, Tutar B, Uyar Y. The Effect of Gastric Helicobacter pylori Colonization on Nasal Functions. Ear Nose Throat J 2019;98:346-50. [PMID: 31018689 DOI: 10.1177/0145561319840825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 149 |
Lee H, Jung HK, Huh KC; Functional Dyspepsia Study Group in the Korean Society of Neurogastroenterology and Motility. Current status of functional dyspepsia in Korea. Korean J Intern Med 2014;29:156-65. [PMID: 24648796 DOI: 10.3904/kjim.2014.29.2.156] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 150 |
Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, Kim JJ. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis. 2015;47:114-118. [PMID: 25467826 DOI: 10.1016/j.dld.2014.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 151 |
Khien VV, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, Binh TT, Dung HDQ, Trang TTH, Yamaoka Y. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13:483-97. [PMID: 31009957 DOI: 10.5009/gnl18137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 152 |
Yogo N, Shihadeh K, Young H, Calcaterra SL, Knepper BC, Burman WJ, Mehler PS, Jenkins TC. Intervention to Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital Discharge: A Novel Stewardship Approach. Infect Control Hosp Epidemiol 2017;38:534-41. [PMID: 28260538 DOI: 10.1017/ice.2017.10] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 153 |
Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci 2020;65:1917-31. [PMID: 32170476 DOI: 10.1007/s10620-020-06193-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 154 |
Sayer JR, Walldén K, Koss H, Allan H, Daviter T, Gane PJ, Waksman G, Tabor AB. Design, synthesis, and evaluation of peptide-imidazo[1,2-a]pyrazine bioconjugates as potential bivalent inhibitors of the VirB11 ATPase HP0525. J Pept Sci 2021;:e3353. [PMID: 34142414 DOI: 10.1002/psc.3353] [Reference Citation Analysis]
|
| 155 |
Huang X, Qu X, Yan W, Huang Y, Cai M, Hu B, Wu L, Lin H, Chen Z, Zhu C. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J. 2010;86:272-278. [PMID: 20448223 DOI: 10.1136/pgmj.2009.089987] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 156 |
Maeng JH, So JW, Kim J, Kim IA, Jung JH, Min K, Lee DH, Yang S. rhEGF-containing thermosensitive and mucoadhesive polymeric sol–gel for endoscopic treatment of gastric ulcer and bleeding. J Biomater Appl 2014;28:1113-21. [DOI: 10.1177/0885328213499948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 157 |
Wang C, Yuan Y, Hunt RH. Helicobacter pylori Infection and Barrett's Esophagus: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2009;104:492-500. [DOI: 10.1038/ajg.2008.37] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 158 |
Tolone S, Pellino V, Vitaliti G, Lanzafame A, Tolone C. Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital J Pediatr. 2012;38:63. [PMID: 23114016 DOI: 10.1186/1824-7288-38-63] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 159 |
Martins GM, Sanches BS, Moretzsohn LD, Lima KS, Cota BD, Coelho LG. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in an urban brazilian population. Arq Gastroenterol. 2016;53:113-117. [PMID: 27305419 DOI: 10.1590/s0004-28032016000200012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 160 |
González-Huezo MS, Rojas-Sánchez A, Rosales-Solís AA, Miranda-Cordero RM, Hinojosa-Ruiz A, Mejía-García E, Cruz-González EG. [Helicobacter pylori eradication frequency with the conventional triple therapy in adult patients at the Centro Médico Issemym]. Rev Gastroenterol Mex. 2012;77:114-118. [PMID: 22921101 DOI: 10.1016/j.rgmx.2012.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 161 |
O'connor A, Taneike I, Nami A, Fitzgerald N, Murphy P, Ryan B, O’connor H, Qasim A, Breslin N, O’moráin C. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol. 2010;22:1123-1127. [PMID: 20354442 DOI: 10.1097/meg.0b013e328338e43d] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 162 |
Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449-1461. [PMID: 19683340 DOI: 10.1016/s0140-6736(09)60938-7] [Cited by in Crossref: 472] [Cited by in F6Publishing: 184] [Article Influence: 36.3] [Reference Citation Analysis]
|
| 163 |
Sereni G, Azzolini F, Camellini L, Formisano D, Decembrino F, Iori V, Tioli C, Cavina M, Di Mario F, Bedogni G, Sassatelli R. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. World J Gastroenterol 2012; 18(33): 4542-4548 [PMID: 22969227 DOI: 10.3748/wjg.v18.i33.4542] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 164 |
Peek RM Jr. New Biology to New Treatment of Helicobacter pylori-Induced Gastric Cancer. Dig Dis 2016;34:510-6. [PMID: 27332886 DOI: 10.1159/000445231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 165 |
Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2011;66:1847-1852. [PMID: 21632579 DOI: 10.1093/jac/dkr217] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 166 |
Sachdeva A, Rawat S, Nagpal J. Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: A review. World J Gastroenterol 2014; 20(3): 724-737 [PMID: 24574746 DOI: 10.3748/wjg.v20.i3.724] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 167 |
Gasparetto M, Pescarin M, Guariso G. Helicobacter pylori Eradication Therapy: Current Availabilities. ISRN Gastroenterol. 2012;2012:186734. [PMID: 22900197 DOI: 10.5402/2012/186734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 168 |
Asadi-Pooya AA, Dehghani SM, Petramfar P, Emami M, Mahmoodi M. Helicobacter pylori infection in patients with epilepsy. Seizure. 2012;21:21-23. [PMID: 21903421 DOI: 10.1016/j.seizure.2011.08.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 169 |
Chung JW, Ha M, Yun SC, Kim JH, Lee JJ, Kim YJ, Kim KO, Kwon KA, Park DK, Lee DH. Meta-analysis: Sequential therapy is superior to conventional therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2013;62:267-271. [PMID: 24262591 DOI: 10.4166/kjg.2013.62.5.267] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 170 |
Murakami TT, Scranton RA, Brown HE, Harris RB, Chen Z, Musuku S, Oren E. Management of Helicobacter Pylori in the United States: Results from a national survey of gastroenterology physicians. Prev Med 2017;100:216-22. [PMID: 28457713 DOI: 10.1016/j.ypmed.2017.04.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 171 |
Yoon HS. Iron deficiency anemia in childhood. J Korean Med Assoc 2011;54:725. [DOI: 10.5124/jkma.2011.54.7.725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 172 |
Gill RS, Collins JS, Talley NJ. Management of noncardiac chest pain in women. Womens Health (Lond) 2012;8:131-43; quiz 144-5. [PMID: 22375717 DOI: 10.2217/whe.12.3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 173 |
Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol 2015; 21(16): 5032-5038 [PMID: 25945019 DOI: 10.3748/wjg.v21.i16.5032] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 174 |
Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295-314. [PMID: 21822447 DOI: 10.1586/ecp.09.8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 175 |
Makobongo MO, Kovachi T, Gancz H, Mor A, Merrell DS. In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. Antimicrob Agents Chemother 2009;53:4231-9. [PMID: 19620333 DOI: 10.1128/AAC.00510-09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 176 |
Wu JC. Gastroesophageal reflux disease: an Asian perspective. J Gastroenterol Hepatol. 2008;23:1785-1793. [PMID: 19120871 DOI: 10.1111/j.1440-1746.2008.05684.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 177 |
Zhou X, Wu J, Zhang G. Association between Helicobacter pylori and asthma: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25:460-468. [PMID: 23242126 DOI: 10.1097/meg.0b013e32835c280a] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 178 |
Chang WC, Jo YI, Park HS, Jegal J, Park JH, Lee JH, Jin CJ. Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients. Clin Exp Nephrol. 2010;14:469-473. [PMID: 20632062 DOI: 10.1007/s10157-010-0319-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 179 |
Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter. 2011;16:131-138. [PMID: 21435091 DOI: 10.1111/j.1523-5378.2011.00826.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 180 |
Kayali S, Aloe R, Bonaguri C, Gaiani F, Manfredi M, Leandro G, Fornaroli F, Di Mario F, De' Angelis GL. Non-invasive tests for the diagnosis of helicobacter pylori: state of the art. Acta Biomed 2018;89:58-64. [PMID: 30561419 DOI: 10.23750/abm.v89i8-S.7910] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 181 |
Zheng HM, Choi MJ, Kim JM, Lee KW, Park YH, Lee DH. In vitro and In vivo Anti-Helicobacter pylori Activities of Centella asiatica Leaf Extract. Prev Nutr Food Sci 2016;21:197-201. [PMID: 27752495 DOI: 10.3746/pnf.2016.21.3.197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 182 |
Lan HC, Chen TS, Li AF, Chang FY, Lin HC. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol. 2012;12:182. [PMID: 23272897 DOI: 10.1186/1471-230x-12-182] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 183 |
Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 184 |
Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. Korean J Gastroenterol. 2013;62:3-26. [PMID: 23954956 DOI: 10.4166/kjg.2013.62.1.3] [Cited by in Crossref: 113] [Cited by in F6Publishing: 75] [Article Influence: 14.1] [Reference Citation Analysis]
|
| 185 |
Eisig JN, Silva FM, Barbuti RC, Rodriguez TN, Malfertheiner P, Moraes Filho JP, Zaterka S. Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication. BMC Gastroenterol. 2009;9:38. [PMID: 19470177 DOI: 10.1186/1471-230X-9-38] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 186 |
Lu B, Li M. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol 2014; 20(19): 5660-5665 [PMID: 24914325 DOI: 10.3748/wjg.v20.i19.5660] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 187 |
Zinzani PL. The many faces of marginal zone lymphoma. Hematology 2012;2012:426-32. [DOI: 10.1182/asheducation.v2012.1.426.3798535] [Cited by in Crossref: 51] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 188 |
Talebi Bezmin Abadi A. Helicobacter pylori: Emergence of a Superbug. Front Med (Lausanne). 2014;1:34. [PMID: 25593908 DOI: 10.3389/fmed.2014.00034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 189 |
Meltzer AC, Pierce R, Cummings DA, Pines JM, May L, Smith MA, Marcotte J, McCarthy ML. Rapid (13)C Urea Breath Test to Identify Helicobacter pylori Infection in Emergency Department Patients with Upper Abdominal Pain. West J Emerg Med 2013;14:278-82. [PMID: 23687549 DOI: 10.5811/westjem.2012.12.15173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 190 |
Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol. 2008;103:510-514. [PMID: 18341483 DOI: 10.1111/j.1572-0241.2008.01819.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 191 |
Kim SB, Lee SH, Kim KO, Jang BI, Kim TN. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection]. Korean J Gastroenterol 2015;66:261-7. [PMID: 26586348 DOI: 10.4166/kjg.2015.66.5.261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 192 |
Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol 2014; 20(18): 5302-5307 [PMID: 24833860 DOI: 10.3748/wjg.v20.i18.5302] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 193 |
Wang CH, Liao ST, Yang J, Li CX, Yang YY, Han R, Chen DF, Lan CH. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. World J Gastroenterol 2015; 21(39): 11179-11184 [PMID: 26494972 DOI: 10.3748/wjg.v21.i39.11179] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 194 |
John S, Baltodano JD, Mehta N, Mark K, Murthy U. Unexplained iron deficiency anemia: does Helicobacter pylori have a role to play? Gastroenterol Rep (Oxf) 2018;6:215-20. [PMID: 30151206 DOI: 10.1093/gastro/goy001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 195 |
Gisbert JP, Pérez-Aisa A, Castro-Fernández M, Barrio J, Rodrigo L, Cosme A, Gisbert JL, Marcos S, Moreno-Otero R. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis. 2010;42:287-290. [PMID: 19632166 DOI: 10.1016/j.dld.2009.06.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 196 |
Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol 2014; 20(18): 5283-5293 [PMID: 24833858 DOI: 10.3748/wjg.v20.i18.5283] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 197 |
Mera RM, Bravo LE, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, Yepez MC, Realpe JL, Schneider BG, Morgan DR, Peek RM, Correa P, Wilson KT, Piazuelo MB. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67:1239-1246. [PMID: 28647684 DOI: 10.1136/gutjnl-2016-311685] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 14.2] [Reference Citation Analysis]
|
| 198 |
Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502-1517. [PMID: 19017521 DOI: 10.1016/j.jacc.2008.08.002] [Cited by in Crossref: 304] [Cited by in F6Publishing: 263] [Article Influence: 21.7] [Reference Citation Analysis]
|
| 199 |
Wong CW, Chung PH, Tam PK, Wong KK. Laparoscopic versus open operation for perforated peptic ulcer in pediatric patients: A 10-year experience. J Pediatr Surg 2015;50:2038-40. [PMID: 26386878 DOI: 10.1016/j.jpedsurg.2015.08.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 200 |
Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371-1386. [PMID: 24758240 DOI: 10.1111/jgh.12607] [Cited by in Crossref: 123] [Cited by in F6Publishing: 90] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 201 |
Lin LC, Hsu TH, Huang KW, Tam KW. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. World J Gastroenterol 2016; 22(23): 5445-5453 [PMID: 27340362 DOI: 10.3748/wjg.v22.i23.5445] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 202 |
Yun CY, Kim N, Lee J, Lee JY, Hwang YJ, Lee HS, Yoon H, Shin CM, Park YS, Kim JW, Lee DH. Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors. Helicobacter. 2018;23:e12542. [PMID: 30303591 DOI: 10.1111/hel.12542] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 203 |
Choi IJ. Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J Intern Med. 2013;28:525-537. [PMID: 24009446 DOI: 10.3904/kjim.2013.28.5.525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 204 |
Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016;388:2355-2365. [PMID: 27769562 DOI: 10.1016/s0140-6736(16)31409-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 205 |
Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: Which regimen first? World J Gastroenterol 2014; 20(3): 665-672 [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 206 |
Kefeli A, Basyigit S, Yeniova AO, Kefeli TT, Aslan M, Tanas O. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. Bosn J Basic Med Sci 2016;16:52-7. [PMID: 26773183 DOI: 10.17305/bjbms.2016.660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 207 |
Tang DM, Kumar S. The Association Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2017;19:5. [PMID: 28155087 DOI: 10.1007/s11894-017-0545-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 208 |
Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105-110. [PMID: 19631287 DOI: 10.1016/j.cgh.2009.07.017] [Cited by in Crossref: 168] [Cited by in F6Publishing: 143] [Article Influence: 12.9] [Reference Citation Analysis]
|
| 209 |
Brownlee AR, Bromberg E, Roslin MS. Outcomes in Patients with Helicobacter pylori Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg 2015;25:2276-9. [PMID: 26001881 DOI: 10.1007/s11695-015-1687-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 210 |
Schulz TR, McBryde ES, Leder K, Biggs BA. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. PLoS One 2014;9:e108610. [PMID: 25268809 DOI: 10.1371/journal.pone.0108610] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 211 |
de Korwin JD. [Does Helicobacter pylori infection play a role in extragastric diseases?]. Presse Med. 2008;37:525-534. [PMID: 18249521 DOI: 10.1016/j.lpm.2007.07.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 212 |
Greenberg ER, Chey WD. Defining the role of sequential therapy for H pylori infection. Lancet. 2013;381:180-182. [PMID: 23158881 DOI: 10.1016/s0140-6736(12)61849-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 213 |
Lee JW, Kim N, Nam RH, Park JH, Kim JM, Jung HC, Song IS. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. Helicobacter. 2011;16:301-310. [PMID: 21762270 DOI: 10.1111/j.1523-5378.2011.00840.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 214 |
Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337.pub2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 215 |
Navarro-Rodriguez T, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, Bogsan CS, Chinzon D, Eisig JN. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013;13:56. [PMID: 23530767 DOI: 10.1186/1471-230x-13-56] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 216 |
Braun M, Föller M, Gulbins E, Lang F. Eryptosis triggered by bismuth. Biometals 2009;22:453-60. [PMID: 19048190 DOI: 10.1007/s10534-008-9180-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 217 |
Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-analysis of randomized clinical trials. PLoS One. 2013;8:e62162. [PMID: 23646118 DOI: 10.1371/journal.pone.0062162] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 218 |
Yuan Y, Leontiadis GI. Levofloxacin-Based Three-Antibiotic Regimen for H. pylori Eradication. American Journal of Gastroenterology 2012;107:1106-7. [DOI: 10.1038/ajg.2012.109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 219 |
He XJ, Zeng XP, Jiang CS, Liu G, Li DZ, Wang W. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial. Arab J Gastroenterol 2021;22:47-51. [PMID: 33551347 DOI: 10.1016/j.ajg.2020.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 220 |
Alaboudy AA, Elbahrawy A, Matsumoto S, Yoshizawa A. Conventional narrow-band imaging has good correlation with histopathological severity of Helicobacter pylori gastritis. Dig Dis Sci 2011;56:1127-30. [PMID: 20857197 DOI: 10.1007/s10620-010-1414-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 221 |
Feng H, Zhou X, Zhang G. Association between cirrhosis and Helicobacter pylori infection: a meta-analysis. Eur J Gastroenterol Hepatol. 2014;26:1309-1319. [PMID: 25304251 DOI: 10.1097/meg.0000000000000220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 222 |
Dacoll C, Sánchez-delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay. Gastroenterología y Hepatología 2017;40:447-54. [DOI: 10.1016/j.gastrohep.2017.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 223 |
Ji R, Li YQ. Diagnosing Helicobacter pylori infection in vivo by novel endoscopic techniques. World J Gastroenterol 2014; 20(28): 9314-9320 [PMID: 25071325 DOI: 10.3748/wjg.v20.i28.9314] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 224 |
Huang TC, Lee CL. Diagnosis, treatment, and outcome in patients with bleeding peptic ulcers and Helicobacter pylori infections. Biomed Res Int. 2014;2014:658108. [PMID: 25101293 DOI: 10.1155/2014/658108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 225 |
Gonen C, Simsek I, Sarioglu S, Akpinar H. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study. Helicobacter. 2009;14:12-21. [PMID: 19191891 DOI: 10.1111/j.1523-5378.2009.00650.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 226 |
Shin DW, Cho J, Kim SH, Kim YJ, Choi HC, Son KY, Park SM, Park JH, Park MS, Cho B. Preferences for the "screen and treat" strategy of Helicobacter pylori to prevent gastric cancer in healthy Korean populations. Helicobacter 2013;18:262-9. [PMID: 23384480 DOI: 10.1111/hel.12039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 227 |
Sapmaz F, Kalkan IH, Suslu I, Demirci H, Atasoy P, Guliter S. Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus. J Dig Dis. 2015;16:531-536. [PMID: 26147605 DOI: 10.1111/1751-2980.12272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 228 |
Chitapanarux T, Thongsawat S, Pisespongsa P, Leerapun A, Kijdamrongthum P. Effect of Bifidobacterium longum on PPI-based triple therapy for eradication of Helicobacter pylori: A randomized, double-blind placebo-controlled study. Journal of Functional Foods 2015;13:289-94. [DOI: 10.1016/j.jff.2015.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 229 |
Pradhan F, Hughes D, Narasimhan RA. Management of Upper Gastrointestinal Bleeding. Hospital Medicine Clinics 2017;6:261-82. [DOI: 10.1016/j.ehmc.2016.11.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 230 |
Sung JK. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection. Korean J Med 2015;89:149-56. [DOI: 10.3904/kjm.2015.89.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 231 |
Mapel D, Roberts M, Overhiser A, Mason A. The epidemiology, diagnosis, and cost of dyspepsia and Helicobacter pylori gastritis: a case-control analysis in the Southwestern United States. Helicobacter. 2013;18:54-65. [PMID: 23067108 DOI: 10.1111/j.1523-5378.2012.00988.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 232 |
O'Connor A, Taneike I, Nami A, Fitzgerald N, Ryan B, Breslin N, O'Connor H, McNamara D, Murphy P, O'Morain C. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci. 2013;182:693-695. [PMID: 23625165 DOI: 10.1007/s11845-013-0957-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 233 |
Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118. [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 234 |
Siao D, Somsouk M. Helicobacter pylori: evidence-based review with a focus on immigrant populations. J Gen Intern Med. 2014;29:520-528. [PMID: 24065381 DOI: 10.1007/s11606-013-2630-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 235 |
Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2017;32:589-594. [PMID: 27505301 DOI: 10.1111/jgh.13510] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 236 |
Chuah SK, Tai WC, Lee CH, Liang CM, Hu TH. Quinolone-containing therapies in the eradication of Helicobacter pylori. Biomed Res Int. 2014;2014:151543. [PMID: 25243116 DOI: 10.1155/2014/151543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 237 |
Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, Schinocca L, Romanelli A, Bonanno G, Linea C, Giustini M, Hassan C, Cottone M, Zullo A. Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study. Dig Liver Dis 2009;41:467-73. [PMID: 18945654 DOI: 10.1016/j.dld.2008.09.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 238 |
Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter. 2013;18:180-186. [PMID: 23305083 DOI: 10.1111/hel.12034] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 239 |
Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34:771-785. [PMID: 25439276 DOI: 10.1016/j.cll.2014.08.008] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 240 |
El-Omar EM. Iron deficiency and Helicobacter pylori-induced gastric cancer: too little, too bad. J Clin Invest 2013;123:113-4. [PMID: 23257355 DOI: 10.1172/JCI67200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 241 |
Campbell R, Kilty SJ, Hutton B, Bonaparte JP. The Role of Helicobacter pylori in Laryngopharyngeal Reflux. Otolaryngol Head Neck Surg. 2017;156:255-262. [PMID: 27803078 DOI: 10.1177/0194599816676052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 242 |
Ozturk T, Sengul D, Sengul I. Helicobacter pylori and association between its positivity and anatomotopographic settlement in the stomach with the host age range. Ann Afr Med 2021;20:1-8. [PMID: 33727504 DOI: 10.4103/aam.aam_69_19] [Reference Citation Analysis]
|
| 243 |
Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-ge L, Yin W, Xie Y. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13. [DOI: 10.1007/s00228-017-2347-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 244 |
Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, Lin JT, Chen MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;43:470-481. [PMID: 26669729 DOI: 10.1111/apt.13495] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 245 |
Perrone S, D'Elia GM, Annechini G, Pulsoni A. Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy. Mediterr J Hematol Infect Dis 2016;8:e2016006. [PMID: 26740867 DOI: 10.4084/MJHID.2016.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 246 |
Emami MH, Zobeiri M, Rahimi H, Arjomandi F, Daghagzadeh H, Adibi P, Hashemi J. N-acetyl cysteine as an adjunct to standard anti-Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open-label trial. Adv Biomed Res 2014;3:189. [PMID: 25298958 DOI: 10.4103/2277-9175.140403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 247 |
Sezgin O, Aydın MK, Özdemir AA, Kanık AE. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol 2019;30:420-35. [PMID: 31060997 DOI: 10.5152/tjg.2019.18693] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 248 |
Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteagudo I, Llorca J, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother. 2012;67:170-173. [PMID: 21965436 DOI: 10.1093/jac/dkr410] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 249 |
Testerman TL, Morris J. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol 2014; 20(36): 12781-12808 [PMID: 25278678 DOI: 10.3748/wjg.v20.i36.12781] [Cited by in CrossRef: 141] [Cited by in F6Publishing: 133] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 250 |
Wu LP, Xuan SH. Advances in research of Helicobacter pylori resistance to levofloxacin. Shijie Huaren Xiaohua Zazhi 2014; 22(2): 197-202 [DOI: 10.11569/wcjd.v22.i2.197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 251 |
Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895-905.e5. [PMID: 25460556 DOI: 10.1016/j.cgh.2014.10.036] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 252 |
Fan F, Wang Z, Li B, Zhang H. Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention: A systematic review and meta‐analysis. J Eval Clin Pract 2019;26:308-15. [DOI: 10.1111/jep.13179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 253 |
Robles-Jara C, Robles-Medranda C, Moncayo M, Landivar B, Parrales J. Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? World J Gastroenterol 2008; 14(18): 2838-2843 [PMID: 18473407 DOI: 10.3748/wjg.14.2838] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 254 |
Yoon H, Lee DH, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N. Optimal initiation of Helicobacter pylori eradication in patients with peptic ulcer bleeding. World J Gastroenterol 2015; 21(8): 2497-2503 [PMID: 25741160 DOI: 10.3748/wjg.v21.i8.2497] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 255 |
Jeong MH, Chung JW, Lee SJ, Ha M, Jeong SH, Na S, Na BS, Park SK, Kim YJ, Kwon KA. [Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori]. Korean J Gastroenterol. 2012;59:401-406. [PMID: 22735872 DOI: 10.4166/kjg.2012.59.6.401] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 256 |
Cheha KM, Dib SOA, Alhalabi MM. Pilot study: Comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of Helicobacter pylori infection in Syrian population single-center experience. Avicenna J Med 2018;8:14-7. [PMID: 29404268 DOI: 10.4103/ajm.AJM_70_17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 257 |
Kasahun GG, Demoz GT, Desta DM. Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review. Infect Drug Resist 2020;13:1567-73. [PMID: 32547126 DOI: 10.2147/IDR.S250200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 258 |
Delchier JC, Bastuji-Garin S, Raymond J, Megraud F, Amiot A, Cambau E, Burucoa C; HELICOSTIC Study Group. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. Med Mal Infect. 2020;50:492-499. [PMID: 31257067 DOI: 10.1016/j.medmal.2019.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 259 |
Kang KK, Lee DH, Oh DH, Yoon H, Shin CM, Park YS, Kim N, Jung HC. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014; 20(22): 6932-6938 [PMID: 24944485 DOI: 10.3748/wjg.v20.i22.6932] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 260 |
Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321-331. [PMID: 18446147 DOI: 10.1038/ncpgasthep1138] [Cited by in Crossref: 212] [Cited by in F6Publishing: 226] [Article Influence: 15.1] [Reference Citation Analysis]
|
| 261 |
Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118. [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 262 |
Huang J, Zhou L, Geng L, Yang M, Xu XW, Ding ZL, Mao M, Wang ZL, Li ZL, Li DY, Gong ST. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. Aliment Pharmacol Ther. 2013;38:1230-1235. [PMID: 24117692 DOI: 10.1111/apt.12516] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 263 |
Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, Dogantzis P, Vlachou E, Kalantzis C, Tsibouris P, Alexandrakis G. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol. 2016;51:145-151. [PMID: 26435055 DOI: 10.3109/00365521.2015.1079646] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 264 |
Kim HD, Kim do H, Park H, Kim WJ, Ahn YS, Lee YJ, Park SM, Seo ES, Park C, Kim YH. Detection of Helicobacter pylori in Gastric Aspirates Using a Monoclonal Antibody-Based Test. Gut Liver. 2013;7:30-34. [PMID: 23423538 DOI: 10.5009/gnl.2013.7.1.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 265 |
Kim YJ, Chung WC, Kim DB. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection. Helicobacter 2021;26:e12792. [PMID: 33650225 DOI: 10.1111/hel.12792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 266 |
van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. Gut 2014;63:1014-23. [DOI: 10.1136/gutjnl-2013-305418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 267 |
Sharara AI, Sarkis FS, El-Halabi MM, Malli A, Mansour NM, Azar C, Eloubeidi MA, Mourad FH, Barada K, Sukkarieh I. Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection. United European Gastroenterol J 2014;2:179-88. [PMID: 25360301 DOI: 10.1177/2050640614530919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 268 |
Yang GH, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Obesity associated with increased risk of gastric Helicobacter pylori infection in an elderly Chinese population. J Am Geriatr Soc 2014;62:190-2. [PMID: 25180384 DOI: 10.1111/jgs.12618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 269 |
Tseng DS, Li D, Cholleti SM, Wei JC, Jodesty Y, Pham HV. Effect of Helicobacter pylori Treatment on Unexplained Iron Deficiency Anemia. Perm J 2019;23:18-195. [PMID: 30939286 DOI: 10.7812/TPP/18-195] [Reference Citation Analysis]
|
| 270 |
Gatta L, Di Mario F, Vaira D, Franzé A, Rugge M, Pilotto A, Lucarini P, Lera M, Fiorini G, Castelli V, Kajo E, Scarpignato C. Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Intern Emerg Med 2011;6:35-9. [DOI: 10.1007/s11739-010-0443-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 271 |
O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010;15 Suppl 1:46-52. [PMID: 21054653 DOI: 10.1111/j.1523-5378.2010.00774.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 272 |
Saleem A, Qasim A, O’Connor HJ, O’Morain CA. Pylera for the eradication of Helicobacter pylori infection. Expert Rev Anti Infect Ther. 2009;7:793-799. [PMID: 19735221 DOI: 10.1586/eri.09.55] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 273 |
Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. Br J Clin Pharmacol. 2009;67:88-98. [PMID: 19076158 DOI: 10.1111/j.1365-2125.2008.03319.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 274 |
Baek SM, Kim N, Kwon YJ, Lee HS, Kim HY, Lee J, Yoon H, Shin CM, Park YS, Lee DH. Role of Serum Pepsinogen II and Helicobacter pylori Status in the Detection of Diffuse-Type Early Gastric Cancer in Young Individuals in South Korea. Gut Liver 2020;14:439-49. [PMID: 31533397 DOI: 10.5009/gnl19091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 275 |
Tsay FW, Tseng HH, Hsu PI, Wang KM, Lee CC, Chang SN, Wang HM, Yu HC, Chen WC, Peng NJ. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol. 2012;27:498-503. [PMID: 21871025 DOI: 10.1111/j.1440-1746.2011.06885.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 276 |
Auttajaroon J, Vilaichone R, Chotivitayatarakorn P, Mahachai V. Once‐daily rabeprazole, levofloxacin, clarithromycin‐MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study). Helicobacter 2019;24. [DOI: 10.1111/hel.12615] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 277 |
Watson JB, Moss SF. Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. Am J Gastroenterol 2011;106:1976-7. [PMID: 22056576 DOI: 10.1038/ajg.2011.309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 278 |
Kim BJ, Kim HS, Song HJ, Chung IK, Kim GH, Kim BW, Shim KN, Jeon SW, Jung YJ, Yang CH, Kim JH, Kim TH, Kim SG, Shin WG, Kim SM, Han SW, Lee JH, Kim KH, Park SK, Park BJ, Lee J, Kim JG; Korean College of Helicobacter and Upper Gastrointestinal Research. Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis. J Korean Med Sci 2016;31:1246-53. [PMID: 27478335 DOI: 10.3346/jkms.2016.31.8.1246] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 279 |
Roesler BM, Costa SC, Zeitune JM. Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer. ISRN Gastroenterol. 2012;2012:935410. [PMID: 22778979 DOI: 10.5402/2012/935410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 280 |
Anthony O'connor JP, O'morain CA. Letter: the ethics of using inferior regimens in H. pylori randomised trials - invited comment. Aliment Pharmacol Ther 2012;35:854-6. [DOI: 10.1111/j.1365-2036.2011.04951.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 281 |
Kim JI, Kim B. Sequential Therapy of Helicobacter pylori Infection. Korean J Helicobacter Up Gastrointest Res 2011;11:103. [DOI: 10.7704/kjhugr.2011.11.2.103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 282 |
Gisbert JP. Enfermedades relacionadas con Helicobacter pylori: dispepsia, úlcera y cáncer gástrico. Gastroenterología y Hepatología 2008;31:18-28. [DOI: 10.1016/s0210-5705(08)76625-1] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 283 |
Fallone CA, Barkun AN, Szilagyi A, Herba KM, Sewitch M, Martel M, Fallone SS. Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can J Gastroenterol 2013;27:397-402. [PMID: 23862170 DOI: 10.1155/2013/801915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 284 |
Shiota S, Yamaoka Y. Management of Helicobacter pylori. F1000 Med Rep. 2010;2. [PMID: 20948865 DOI: 10.3410/m2-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 285 |
Hung IF, Chan P, Leung S, Chan FS, Hsu A, But D, Seto WK, Wong SY, Chan CK, Gu Q. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter. 2009;14:505-511. [PMID: 19889067 DOI: 10.1111/j.1523-5378.2009.00722.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 286 |
Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011;34:604-617. [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 287 |
Hu B, Zhao F, Wang S, Olszewski MA, Bian H, Wu Y, Kong M, Xu L, Miao Y, Fang Y, Yang C, Zhao H, Zhang Y. A high-throughput multiplex genetic detection system for Helicobacter pylori identification, virulence and resistance analysis. Future Microbiol 2016;11:1261-78. [PMID: 27023051 DOI: 10.2217/fmb-2016-0023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 288 |
Riahizadeh S, Malekzadeh R, Agah S, Zendehdel N, Sotoudehmanesh R, Ebrahimi-Dariani N, Pourshams A, Vahedi H, Mikaeli J, Khatibian M. Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. Helicobacter. 2010;15:497-504. [PMID: 21073605 DOI: 10.1111/j.1523-5378.2010.00798.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 289 |
Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, Hanyu O, Shimano H, Sone H. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106:81-87. [PMID: 25110103 DOI: 10.1016/j.diabres.2014.07.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 290 |
Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao S, Tan HJ, Wu C, Jung HC, Hoang BH, Kachintorn U, Goh K, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2009;24:1587-600. [DOI: 10.1111/j.1440-1746.2009.05982.x] [Cited by in Crossref: 357] [Cited by in F6Publishing: 353] [Article Influence: 27.5] [Reference Citation Analysis]
|
| 291 |
Chuah Y, Wu D, Chuah S, Yang J, Lee T, Yeh H, Chen C, Liu Y, Hsu P. Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey). Helicobacter 2017;22:e12380. [DOI: 10.1111/hel.12380] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 292 |
Verma S, Sharma D, Kanwar P, Sohn W, Mohanty SR, Tortolani AJ, Gorecki P. Prevalence of Helicobacter pylori infection in bariatric patients: a histologic assessment. Surg Obes Relat Dis. 2013;9:679-685. [PMID: 23246321 DOI: 10.1016/j.soard.2012.10.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 293 |
Choi JM, Kim SG. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection: Korean and Overseas Guidelines. Korean J Med 2015;89:157-68. [DOI: 10.3904/kjm.2015.89.2.157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 294 |
Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol 2015; 21(41): 11654-11672 [PMID: 26556993 DOI: 10.3748/wjg.v21.i41.11654] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 295 |
Garcia M, Raymond J, Garnier M, Cremniter J, Burucoa C. Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrob Agents Chemother. 2012;56:550-551. [PMID: 22064536 DOI: 10.1128/AAC.05243-11] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 296 |
Kelly JJ, Perugini RA, Wang QL, Czerniach DR, Flahive J, Cohen PA. The presence of Helicobacter pylori is not associated with long-term anastomotic complications in gastric bypass patients. Surg Endosc 2015;29:2885-90. [PMID: 25552229 DOI: 10.1007/s00464-014-4022-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 297 |
Peura DA, Crowe SE. Helicobacter pylori. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 833-843.e4. [DOI: 10.1016/b978-1-4160-6189-2.00050-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 298 |
Zhang XH, He Y, Feng R, Xu LP, Jiang Q, Jiang H, Lu J, Fu HX, Liu H, Wang JW, Wang QM, Feng FE, Zhu XL, Xu LL, Xie YD, Ma H, Wang H, Liu KY, Huang XJ. Helicobacter pylori infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets 2016;27:223-9. [PMID: 26338255 DOI: 10.3109/09537104.2015.1077946] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 299 |
Weiner N, Shaoul R. Impact of Age, Gender, and Addition of Probiotics on Treatment Success for Helicobacter pylori in Children. Glob Pediatr Health 2015;2:2333794X15607798. [PMID: 27335981 DOI: 10.1177/2333794X15607798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 300 |
Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of Helicobacter pylori in West Flanders - Belgium: an observational cross-sectional study. Acta Clin Belg 2021;:1-8. [PMID: 33502281 DOI: 10.1080/17843286.2021.1872307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 301 |
Shaikh T, Fallone CA. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice. Can J Gastroenterol Hepatol 2016;2016:7321574. [PMID: 27446864 DOI: 10.1155/2016/7321574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 302 |
Ullah H, Di Minno A, Santarcangelo C, Khan H, Xiao J, Arciola CR, Daglia M. Vegetable Extracts and Nutrients Useful in the Recovery from Helicobacter pylori Infection: A Systematic Review on Clinical Trials. Molecules 2021;26:2272. [PMID: 33919894 DOI: 10.3390/molecules26082272] [Reference Citation Analysis]
|
| 303 |
Suzuki RB, Lopes RA, da Câmara Lopes GA, Hung Ho T, Sperança MA. Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol 2013;13:164. [PMID: 24305035 DOI: 10.1186/1471-230X-13-164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 304 |
Cho SJ, Choi IJ, Kook MC, Yoon H, Park S, Kim CG, Lee JY, Lee JH, Ryu KW, Kim YW. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther. 2013;38:477-489. [PMID: 23822578 DOI: 10.1111/apt.12402] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 305 |
Allen JI, Katzka D, Robert M, Leontiadis GI. American Gastroenterological Association Institute Technical Review on the Role of Upper Gastrointestinal Biopsy to Evaluate Dyspepsia in the Adult Patient in the Absence of Visible Mucosal Lesions. Gastroenterology 2015;149:1088-118. [DOI: 10.1053/j.gastro.2015.07.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 306 |
Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, Das R. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. J Glob Antimicrob Resist. 2016;6:39-43. [PMID: 27530837 DOI: 10.1016/j.jgar.2016.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 307 |
Sugimoto M, Wu JY, Abudayyeh S, Hoffman J, Brahem H, Al-Khatib K, Yamaoka Y, Graham DY. Unreliability of results of PCR detection of Helicobacter pylori in clinical or environmental samples. J Clin Microbiol. 2009;47:738-742. [PMID: 19129407 DOI: 10.1128/jcm.01563-08] [Cited by in Crossref: 44] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 308 |
Pintar T, Kaliterna N, Carli T. The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery. J Int Med Res 2018;46:2696-707. [PMID: 29690823 DOI: 10.1177/0300060518769543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 309 |
Leung Ki EL, Chan FK. Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. Best Pract Res Clin Gastroenterol. 2012;26:163-172. [PMID: 22542154 DOI: 10.1016/j.bpg.2012.01.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 310 |
Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 311 |
Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10:168-174. [PMID: 23358394 DOI: 10.1038/nrgastro.2013.9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 85] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 312 |
Caicedo Ochoa EY, Quintero Moreno CO, Méndez Fandiño YR, Sánchez Fonseca SC, Cortes Motta HF, Guio Guerra SA. Assessment of the use of vitamin C and E supplements concomitantly to antibiotic treatment against Helicobacter pylori: A systematic review and meta-analysis. Med Clin (Barc) 2018;151:45-52. [PMID: 29102269 DOI: 10.1016/j.medcli.2017.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 313 |
Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter. 2009;14:61-65. [PMID: 19191898 DOI: 10.1111/j.1523-5378.2009.00655.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 314 |
Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, Wu JY, Kuo CH, Huang YK, Wu DC. Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol. 2015;21:11221-11235. [PMID: 26523098 DOI: 10.3748/wjg.v21.i40.11221.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 315 |
Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci. 2008;53:2896-2903. [PMID: 18452057 DOI: 10.1007/s10620-008-0255-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 316 |
Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol. 2010;48:3703-3707. [PMID: 20668128 DOI: 10.1128/jcm.00144-10] [Cited by in Crossref: 76] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 317 |
Tonkić A, Tonkić M, Brnić D. Increasing Prevalence of Primary Clarithromycin Resistance in Helicobacter pylori Strains in Split, Croatia. Journal of Chemotherapy 2013;21:598-9. [DOI: 10.1179/joc.2009.21.5.598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 318 |
Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am. 2011;21:613-635. [PMID: 21944414 DOI: 10.1016/j.giec.2011.07.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 319 |
Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One 2016;11:e0160007. [PMID: 27454429 DOI: 10.1371/journal.pone.0160007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 320 |
Park JY, Dunbar KB, Mitui M, Arnold CA, Lam-Himlin DM, Valasek MA, Thung I, Okwara C, Coss E, Cryer B, Doern CD. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. Dig Dis Sci 2016;61:2373-80. [PMID: 26923948 DOI: 10.1007/s10620-016-4091-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 321 |
Rhodes LA PharmD. Practical considerations for managing Helicobacter pylori in college health. J Am Coll Health 2017;65:361-2. [PMID: 28622096 DOI: 10.1080/07448481.2017.1341901] [Reference Citation Analysis]
|
| 322 |
de Korwin JD. Helicobacter pylori. Gastroentérologie Clinique et Biologique 2007;31:1110-7. [DOI: 10.1016/s0399-8320(07)78346-x] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 323 |
Glickman JN, Noffsinger A, Nevin DT, Ray M, Lash RH, Genta RM. Helicobacter infections with rare bacteria or minimal gastritis: Expecting the unexpected. Digestive and Liver Disease 2015;47:549-55. [DOI: 10.1016/j.dld.2015.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 324 |
Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014;58:5936-5942. [PMID: 25070099 DOI: 10.1128/aac.02922-14] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 325 |
Buzás GM. First-line eradication of Helicobacter pylori: Are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16(31): 3865-3870 [PMID: 20712046 DOI: 10.3748/wjg.v16.i31.3865] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 326 |
Redéen S, Petersson F, Törnkrantz E, Levander H, Mårdh E, Borch K. Reliability of Diagnostic Tests for Helicobacter pylori Infection. Gastroenterol Res Pract 2011;2011:940650. [PMID: 21826138 DOI: 10.1155/2011/940650] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 327 |
Roberts BP, Miller BR 3rd, Roitberg AE, Merz KM Jr. Wide-open flaps are key to urease activity. J Am Chem Soc 2012;134:9934-7. [PMID: 22670767 DOI: 10.1021/ja3043239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 328 |
Jung YS, Lee SH, Park CS, Oh MJ, Kim KO, Jang BI, Jeon SW, Jung MK, Park KS, Kim ES, Cho KB, Jung JT, Kwon JG, Kim EY, Kim WJ, Yang CH. Trends in the Eradication Rates of Helicobacter pylori Infection in Daegu and Gyeongsangbuk-do, Korea: Multicenter Study over 13 Years. Korean J Gastroenterol 2014;63:82. [DOI: 10.4166/kjg.2014.63.2.82] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 329 |
Upala S, Jaruvongvanich V, Riangwiwat T, Jaruvongvanich S, Sanguankeo A. Association between Helicobacter pylori infection and metabolic syndrome: a systematic review and meta-analysis: H. pylori and metabolic syndrome. Journal of Digestive Diseases 2016;17:433-40. [DOI: 10.1111/1751-2980.12367] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 330 |
Farah R, Khamisy-Farah R. Association of neutrophil to lymphocyte ratio with presence and severity of gastritis due to Helicobacter pylori infection. J Clin Lab Anal. 2014;28:219-223. [PMID: 24478129 DOI: 10.1002/jcla.21669] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 331 |
Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther. 2011;9:581-588. [PMID: 21819326 DOI: 10.1586/eri.11.80] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 332 |
Yamamoto T, Matsui H, Yamaji K, Takahashi T, Øverby A, Nakamura M, Matsumoto A, Nonaka K, Sunazuka T, Ōmura S, Nakano H. Narrow-spectrum inhibitors targeting an alternative menaquinone biosynthetic pathway of Helicobacter pylori. Journal of Infection and Chemotherapy 2016;22:587-92. [DOI: 10.1016/j.jiac.2016.05.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 333 |
Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JM, Jung HC. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter. 2013;18:135-142. [PMID: 23066652 DOI: 10.1111/hel.12018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 334 |
Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol 2014; 20(28): 9439-9450 [PMID: 25071338 DOI: 10.3748/wjg.v20.i28.9439] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
|
| 335 |
Gökışık MT, Uyar S. The role of Helicobacter pylori in vitamin-B12 deficiency due to metformin use. Helicobacter 2020;25:e12718. [PMID: 32559822 DOI: 10.1111/hel.12718] [Reference Citation Analysis]
|
| 336 |
Kiss S, Zsikla V, Frank A, Willi N, Cathomas G. Helicobacter- negative gastritis: polymerase chain reaction for Helicobacter DNA is a valuable tool to elucidate the diagnosis. Aliment Pharmacol Ther 2016;43:924-32. [DOI: 10.1111/apt.13564] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 337 |
Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014;80:384-392. [PMID: 25512154 DOI: 10.1016/j.aogh.2014.09.013] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 13.4] [Reference Citation Analysis]
|
| 338 |
Lee KH, Park SY, Jeong SJ, Jung DH, Kim JH, Jeong SH, Kang IM, Song YG. Can Aminoglycosides Be Used as a New Treatment for Helicobacter pylori? In vitro Activity of Recently Isolated Helicobacter pylori. Infect Chemother 2019;51:10-20. [PMID: 30941933 DOI: 10.3947/ic.2019.51.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 339 |
Chotivitayatarakorn P, Mahachai V, Vilaichone RK. Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev 2017;18:2839-43. [PMID: 29072432 DOI: 10.22034/APJCP.2017.18.10.2839] [Reference Citation Analysis]
|
| 340 |
Best LM, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, Yaghoobi M, Gurusamy KS. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3:CD012080. [PMID: 29543326 DOI: 10.1002/14651858.cd012080.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 341 |
Hsu PI, Kao SS, Wu DC, Chen WC, Peng NJ, Yu HC, Wang HM, Lai KH, Cheng JS, Chen A. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine (Baltimore). 2015;94:e2104. [PMID: 26632893 DOI: 10.1097/md.0000000000002104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 342 |
Grande R, Carradori S, Puca V, Vitale I, Angeli A, Nocentini A, Bonardi A, Gratteri P, Lanuti P, Bologna G, Simeone P, Capasso C, De Luca V, Supuran CT. Selective Inhibition of Helicobacter pylori Carbonic Anhydrases by Carvacrol and Thymol Could Impair Biofilm Production and the Release of Outer Membrane Vesicles. Int J Mol Sci 2021;22:11583. [PMID: 34769015 DOI: 10.3390/ijms222111583] [Reference Citation Analysis]
|
| 343 |
Lin MH, Cheng HT, Chuang WY, Yu LK, Tsou YK, Lee MS. Histological examination of ulcer margin for diagnosing Helicobacter pylori infection in patients with gastric ulcers. Ann Diagn Pathol. 2013;17:63-66. [PMID: 22981783 DOI: 10.1016/j.anndiagpath.2012.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 344 |
Wilhelm SM, Johnson JL, Kale-pradhan PB. Treating Bugs with Bugs: The Role of Probiotics as Adjunctive Therapy for Helicobacter pylori. Ann Pharmacother 2011;45:960-6. [DOI: 10.1345/aph.1q104] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 345 |
Navarro-Rodriguez T, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, Bogsan CS, Chinzon D, Eisig JN. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013;13:56. [PMID: 23530767 DOI: 10.1186/1471-230x-13-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 346 |
Wang J, Li WT, Zheng YX, Zhao SS, Li N, Huang Y, Zhou RR, Huang ZB, Fan XG. The Association between Helicobacter pylori Infection and Chronic Hepatitis C: A Meta-Analysis and Trial Sequential Analysis. Gastroenterol Res Pract 2016;2016:8780695. [PMID: 26904112 DOI: 10.1155/2016/8780695] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 347 |
Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118:1894-1909. [PMID: 18836135 DOI: 10.1161/circulationaha.108.191087] [Cited by in Crossref: 305] [Cited by in F6Publishing: 88] [Article Influence: 21.8] [Reference Citation Analysis]
|
| 348 |
Kim HW, Kim GH, Cheong JY, Yang US, Park SK, Song CS, Kang DH, Song GA. H pylori eradication: A randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol 2008; 14(6): 908-912 [PMID: 18240348 DOI: 10.3748/wjg.14.908] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 349 |
Abdul Rahim NR, Benson J, Grocke K, Vather D, Zimmerman J, Moody T, Mwanri L. Prevalence of Helicobacter pylori infection in newly arrived refugees attending the Migrant Health Service, South Australia. Helicobacter 2017;22:e12360. [DOI: 10.1111/hel.12360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 350 |
Yuan C, Lin XM, Ou Y, Cai L, Cheng Q, Zhou P, Liao J. Association between regular arrangement of collecting venules and Helicobacter pylori status in routine endoscopy. BMC Gastroenterol 2021;21:389. [PMID: 34670510 DOI: 10.1186/s12876-021-01960-w] [Reference Citation Analysis]
|
| 351 |
Frater JL. Trends in iron deficiency anemia research 2001-2020: A bibliometric analysis. World J Meta-Anal 2021; 9(4): 389-404 [DOI: 10.13105/wjma.v9.i4.389] [Reference Citation Analysis]
|
| 352 |
Prasertpetmanee S, Mahachai V, Vilaichone RK. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter. 2013;18:270-273. [PMID: 23356886 DOI: 10.1111/hel.12041] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 353 |
Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014;19:243-248. [PMID: 25056262 DOI: 10.1111/hel.12146] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 13.1] [Reference Citation Analysis]
|
| 354 |
Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PMID: 23331077 DOI: 10.1517/14656566.2013.763926] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 355 |
Manfredi M, Bizzarri B, de’Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter. 2012;17:246-253. [PMID: 22759323 DOI: 10.1111/j.1523-5378.2012.00945.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 356 |
Hylek EM, Solarz DE. Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination. JACC Cardiovasc Interv 2008;1:62-4. [PMID: 19393146 DOI: 10.1016/j.jcin.2007.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 357 |
Kessenich CR, Erigo-backsman RC. Gastritis and noninvasive testing for Helicobacter pylori. The Nurse Practitioner 2012;37:7-9. [DOI: 10.1097/01.npr.0000412901.86759.5c] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 358 |
Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34:1255-1268. [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 359 |
Liu KSH, Hung IFN, Seto WKW, Tong T, Hsu ASJ, Lam FYF, But DYK, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014;63:1410-5. [DOI: 10.1136/gutjnl-2013-306120] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 360 |
Chan CC, Chien NH, Lee CL, Yang YC, Hung CS, Tu TC, Wu CH. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. BMC Gastroenterol 2015;15:170. [PMID: 26635102 DOI: 10.1186/s12876-015-0401-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 361 |
Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, Imai R, Fujisawa T, Mori H, Matsuda Y, Wada S, Horiuchi A, Kiyosawa K. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Can J Gastroenterol Hepatol. 2017;2017:4385161. [PMID: 28349044 DOI: 10.1155/2017/4385161] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 362 |
Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014; 20(29): 9912-9921 [PMID: 25110421 DOI: 10.3748/wjg.v20.i29.9912] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 73] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 363 |
Smith SM, Haider RB, O'Connor H, McNamara D, O'Morain C. Practical treatment of Helicobacter pylori: a balanced view in changing times. Eur J Gastroenterol Hepatol. 2014;26:819-825. [PMID: 24892516 DOI: 10.1097/meg.0000000000000130] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 364 |
Liu X, Wang H, Lv Z, Wang Y, Wang B, Xie Y, Zhou X, Lv N. Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2015;2015:415648. [PMID: 26106411 DOI: 10.1155/2015/415648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 365 |
Ferreira J, Moss SF. Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection. Curr Treat Options Gastroenterol. 2014;12:373-384. [PMID: 25187235 DOI: 10.1007/s11938-014-0027-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 366 |
Farah R, Hamza H, Khamisy-Farah R. A link between platelet to lymphocyte ratio and Helicobacter pylori infection. J Clin Lab Anal 2018;32. [PMID: 28374931 DOI: 10.1002/jcla.22222] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 367 |
Miendje Deyi VY, Burette A, Bentatou Z, Maaroufi Y, Bontems P, Lepage P, Reynders M. Practical use of GenoType® HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing. Diagn Microbiol Infect Dis. 2011;70:557-560. [PMID: 21696906 DOI: 10.1016/j.diagmicrobio.2011.05.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 368 |
Onyekwere CA, Odiagah JN, Igetei R, Duro Emanuel AO, Ekere F, Smith S. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: Report of an efficacy study. World J Gastroenterol 2014; 20(13): 3615-3619 [PMID: 24707145 DOI: 10.3748/wjg.v20.i13.3615] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 369 |
Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, Le TK, Quek K, Pham VH. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000Res 2016;5:671. [PMID: 27583131 DOI: 10.12688/f1000research.8239.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 370 |
Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH. The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole. Gut Liver. 2010;4:201-206. [PMID: 20559522 DOI: 10.5009/gnl.2010.4.2.201] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 371 |
Li J, Yang W, Cui R, Wang D, Chang Y, Gu W, Yin W, Bai X, Chen K, Xia L, Geng H, Xing G. Metabolizer in vivo of fullerenes and metallofullerenes by positron emission tomography. Nanotechnology 2016;27:155101. [DOI: 10.1088/0957-4484/27/15/155101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 372 |
Mannon PJ. Immunological Diseases of the Gastrointestinal Tract. Clinical Immunology. Elsevier; 2019. pp. 1005-1019.e1. [DOI: 10.1016/b978-0-7020-6896-6.00075-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 373 |
Zhou S, Marklund H, Blaha O, Desai M, Martin B, Bingham D, Berry GJ, Gomulia E, Ng AY, Shen J. Deep learning assistance for the histopathologic diagnosis of Helicobacter pylori. Intelligence-Based Medicine 2020;1-2:100004. [DOI: 10.1016/j.ibmed.2020.100004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 374 |
Yang Y, Xiong W, Wang S, Xu J, McNutt MA, Zhang L. Factors Associated With Detection of Helicobacter pylori in Gastric Biopsies: A Case-Control Study of 396 Biopsies. Appl Immunohistochem Mol Morphol 2018;26:345-50. [PMID: 27490761 DOI: 10.1097/PAI.0000000000000421] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 375 |
Zhang X, Jiang A, Qi B, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Appl Microbiol Biotechnol 2018;102:4817-27. [DOI: 10.1007/s00253-018-8982-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 376 |
Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori A systematic review and meta-analysis. Scand J Gastroenterol. 2014;49:528-538. [PMID: 24611790 DOI: 10.3109/00365521.2014.887765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 377 |
Rasooly MM, Moye NA, Kirshenbaum AS. Helicobacter pylori: A significant and treatable cause of chronic urticaria and angioedema. Nurse Pract. 2015;40:1-6. [PMID: 26383021 DOI: 10.1097/01.NPR.0000471366.32982.f2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 378 |
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 310] [Cited by in F6Publishing: 288] [Article Influence: 44.3] [Reference Citation Analysis]
|
| 379 |
Yep-Gamarra V, Díaz-Vélez C, Araujo I, Ginès À, Fernández-Esparrach G. [Usefulness of systematic chromoendoscopy with a double dye staining technique for the detection of dysplasia in patients with premalignant gastric lesions]. Gastroenterol Hepatol 2016;39:49-54. [PMID: 26548735 DOI: 10.1016/j.gastrohep.2015.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 380 |
Denlinger NM, Epperla N, William BM. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res 2018;10:615-24. [PMID: 29628774 DOI: 10.2147/CMAR.S133291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 381 |
Yoon H, Lee DH, Kim N, Park YS, Shin CM, Kang KK, Oh DH, Jang DK, Chung JW. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol. 2013;28:1801-1809. [PMID: 24118110 DOI: 10.1111/jgh.12397] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 382 |
Koff JL, Chihara D, Phan A, Nastoupil LJ, Williams JN, Flowers CR. To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. Curr Hematol Malig Rep 2015;10:244-55. [PMID: 26104907 DOI: 10.1007/s11899-015-0267-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 383 |
Lü M, Yu S, Deng J, Yan Q, Yang C, Xia G, Zhou X. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One 2016;11:e0163743. [PMID: 27723762 DOI: 10.1371/journal.pone.0163743] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 384 |
Salvador JA, Figueiredo SA, Pinto RM, Silvestre SM. Bismuth compounds in medicinal chemistry. Future Med Chem 2012;4:1495-523. [PMID: 22857536 DOI: 10.4155/fmc.12.95] [Cited by in Crossref: 60] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 385 |
Yoon SB, Park JM, Lee JY, Baeg MK, Lim CH, Kim JS, Cho YK, Lee IS, Kim SW, Choi MG. Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates. World J Gastroenterol 2014; 20(4): 1061-1066 [PMID: 24574779 DOI: 10.3748/wjg.v20.i4.1061] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 386 |
Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 387 |
Momeni A, Rahimian G, Kiasi A, Amiri M, Kheiri S. Effect of licorice versus bismuth on eradication of Helicobacter pylori in patients with peptic ulcer disease. Pharmacognosy Res 2014;6:341-4. [PMID: 25276073 DOI: 10.4103/0974-8490.138289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 388 |
Nelson ND, Tondon R, Fortuna D, Westerhoff M, Swanson PE, Furth E. Helicobacter pylori Antigen But Not the Organism Is Occasionally Present Within Germinal Centers: Implications for Patient Management and Biology. Am J Surg Pathol 2020;44:1528-34. [PMID: 32657781 DOI: 10.1097/PAS.0000000000001542] [Reference Citation Analysis]
|
| 389 |
Sepulveda AR. Helicobacter, Inflammation, and Gastric Cancer. Curr Pathobiol Rep. 2013;1:9-18. [PMID: 23687623 DOI: 10.1007/s40139-013-0009-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 390 |
den Hollander WJ, Kuipers EJ. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother. 2012;13:2625-2636. [PMID: 23167300 DOI: 10.1517/14656566.2012.747510] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 391 |
Ioannidou P, Papanikolaou D, Mikos T, Mastorakos G, Goulis DG. Predictive factors of Hyperemesis Gravidarum: A systematic review. Eur J Obstet Gynecol Reprod Biol 2019;238:178-87. [PMID: 31126753 DOI: 10.1016/j.ejogrb.2019.04.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 392 |
Yuksel Sert S, Ozturk A, Bektas A, Cengiz MI. Periodontal treatment is more effective in gastric Helicobacter pylori eradication in those patients who maintain good oral hygiene. International Dental Journal 2019;69:392-9. [DOI: 10.1111/idj.12484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 393 |
Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013;309:578-586. [PMID: 23403682 DOI: 10.1001/jama. 2013.311] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 394 |
Liu MK, Wu IC, Lu CY, Kuo CH, Yu FJ, Liu CJ, Hsu PI, Hsu WH, Su YC, Chen A. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens. Kaohsiung J Med Sci. 2013;29:379-384. [PMID: 23768702 DOI: 10.1016/j.kjms.2012.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 395 |
Vilaichone RK, Quach DT, Yamaoka Y, Sugano K, Mahachai V. Prevalence and Pattern of Antibiotic Resistant Strains of Helicobacter Pylori Infection in ASEAN. Asian Pac J Cancer Prev 2018;19:1411-3. [PMID: 29802708 DOI: 10.22034/APJCP.2018.19.5.1411] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
|
| 396 |
Harb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2015;42:131-41. [PMID: 26011564 DOI: 10.1111/apt.13259] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 397 |
Guariso G, Gasparetto M. Update on Peptic Ulcers in the Pediatric Age. Ulcers 2012;2012:1-9. [DOI: 10.1155/2012/896509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 398 |
. Peptic Ulcer Disease: Clinically Relevant Causes and Treatments. ORTHOPEDICS 2009;32. [DOI: 10.3928/01477447-20090201-25] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 399 |
Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. 2014;2014:124607. [PMID: 24800203 DOI: 10.1155/2014/124607] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 400 |
Klein S, Gildenblat J, Ihle MA, Merkelbach-Bruse S, Noh KW, Peifer M, Quaas A, Büttner R. Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies. BMC Gastroenterol 2020;20:417. [PMID: 33308189 DOI: 10.1186/s12876-020-01494-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 401 |
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States. Patient Prefer Adherence 2016;10:45-55. [PMID: 26855566 DOI: 10.2147/PPA.S93320] [Reference Citation Analysis]
|
| 402 |
Kubra Hussaini SZ, Humaira Hussaini SZ, Yasmeen R, Unnisa B, Syed AAA, Khan MN, Hassan SI. Comparison of efficacy and pharmacoeconomics of two Helicobacter pylori eradication regimens in peptic ulcer disease. Perspect Clin Res 2018;9:4-8. [PMID: 29430411 DOI: 10.4103/picr.PICR_99_16] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 403 |
Miura S, Hokari R. Seeking an optimal eradication therapy for Helicobacter pylori infection: Editorials. Journal of Gastroenterology and Hepatology 2012;27:7-9. [DOI: 10.1111/j.1440-1746.2011.06953.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 404 |
Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: High-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-877. [PMID: 18644011 DOI: 10.1111/j.1365-2036.2008.03807.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 31] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 405 |
Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter. 2012;17:282-285. [PMID: 22759328 DOI: 10.1111/j.1523-5378.2012.00953.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 406 |
Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication. World J Gastroenterol 2015; 21(18): 5568-5574 [PMID: 25987781 DOI: 10.3748/wjg.v21.i18.5568] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 407 |
Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett 2014;355:106-12. [PMID: 25218349 DOI: 10.1016/j.canlet.2014.09.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 408 |
Kobayashi Y, Hatta Y, Hojo A, Kura Y, Uchino Y, Takahashi H, Kiso S, Hirabayashi Y, Yagi M, Kodaira H, Kurita D, Tanaka T, Miura K, Iriyama N, Kobayashi S, Sawada U, Sugitani M, Takeuchi J. Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Exp Ther Med 2012;3:304-8. [PMID: 22969886 DOI: 10.3892/etm.2011.387] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 409 |
Dugan K, Ablah E, Okut H, Srinivasan S, Salyers W Jr. Guideline Adherence in Dyspepsia Investigation and Treatment. Kans J Med 2020;13:306-10. [PMID: 33343824 DOI: 10.17161/kjm.vol13.13838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 410 |
Koussoulas V, Giamarellos-bourboulis EJ, Barbatzas C, Pimentel M. Serum sTREM-1 as a Surrogate Marker of Treatment Outcome in Patients with Peptic Ulcer Disease. Dig Dis Sci 2011;56:3590-5. [DOI: 10.1007/s10620-011-1761-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 411 |
Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, Vaira D. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol. 2009;104:1932-197; quiz 1938. [PMID: 19532131 DOI: 10.1038/ajg.2009.314] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 412 |
Silva O, Viegas S, de Mello-Sampayo C, Costa MJ, Serrano R, Cabrita J, Gomes ET. Anti-Helicobacter pylori activity of Terminalia macroptera root. Fitoterapia. 2012;83:872-876. [PMID: 22465506 DOI: 10.1016/j.fitote.2012.03.019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 413 |
Üçüncü MZ, Kabul Gürbulak E, Gürbulak B, Savaş OA, Özütürk B, Dural AC, Haşlak A. Relationship between atrophic gastritis, gastric intestinal metaplasia and Helicobacter pylori on endoscopic screening of upper gastrointestinal tract and a brief review of the literature: Endoscopic screening of upper gastrointestinal tract for gastric mucosal disorders. Eur Surg 2016;48:99-104. [DOI: 10.1007/s10353-015-0378-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 414 |
Sari YS, Can D, Tunali V, Sahin O, Koc O, Bender O. H pylori: Treatment for the patient only or the whole family? World J Gastroenterol 2008; 14(8): 1244-1247 [PMID: 18300351 DOI: 10.3748/wjg.14.1244] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 415 |
Richter V, Gonzalez JO, Hazan S, Gottlieb G, Friedenberg K, Gatof D, Ganeshappa R, Delgado JS, Abramowitz D, Hardi R, Coates A, Haq M, Mehta N, Jones BA, Moss SF, Shirin H. The validity of breath collection bags method in detecting Helicobacter pylori using the novel BreathID ® Hp Lab System: a multicenter clinical study in 257 subjects. Ther Adv Gastrointest Endosc 2019;12:2631774519843401. [PMID: 31192315 DOI: 10.1177/2631774519843401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 416 |
Wang H, Ran J, Jiang T. Urea. Subcell Biochem 2014;73:7-29. [PMID: 25298336 DOI: 10.1007/978-94-017-9343-8_2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 417 |
Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 418 |
Hayashi S, Imamura J, Kimura K, Saeki S, Hishima T. Endoscopic features of lymphoid follicles in Helicobacter pylori-associated chronic gastritis. Dig Endosc. 2015;27:53-60. [PMID: 25092073 DOI: 10.1111/den.12335] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 419 |
Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection. Biomed Res Int. 2014;2014:158520. [PMID: 24995271 DOI: 10.1155/2014/158520] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 420 |
Broide E, Shirin H. Evaluation of Exalenz Bioscience's BreathID for Helicobacter pylori detection. Expert Rev Mol Diagn 2015;15:299-312. [PMID: 25634297 DOI: 10.1586/14737159.2015.982537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 421 |
Kitila KT, Sori LM, Desalegn DM, Tullu KD. Burden of Helicobacter pylori Infections and Associated Risk Factors among Women of Child Bearing Age in Addis Ababa, Ethiopia. Int J Chronic Dis 2018;2018:5183713. [PMID: 30538998 DOI: 10.1155/2018/5183713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 422 |
Park Y, Kim TJ, Lee H, Yoo H, Sohn I, Min YW, Min BH, Lee JH, Rhee PL, Kim JJ. Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study. Helicobacter 2021;26:e12783. [PMID: 33508177 DOI: 10.1111/hel.12783] [Reference Citation Analysis]
|
| 423 |
Herardi R, Syam AF, Simadibrata M, Setiati S, Darnindro N, Abdullah M, Makmun D. Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population: Double-Blinded Randomized Clinical Trial. Asian Pac J Cancer Prev 2020;21:19-24. [PMID: 31983158 DOI: 10.31557/APJCP.2020.21.1.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 424 |
Zare Javid A, Maghsoumi-Norouzabad L, Bazyar H, Aghamohammadi V, Alavinejad P. Effects of Concurrent Omega-3 and Cranberry Juice Consumption Along with Standard Antibiotic Therapy on the Eradication of Helicobacter pylori, Gastrointestinal Symptoms, Some Serum Inflammatory and Oxidative Stress Markers in Adults with Helicobacter pylori Infection: A Study Protocol for a Randomized Controlled Trial. Infect Drug Resist 2020;13:3179-85. [PMID: 32982332 DOI: 10.2147/IDR.S270057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 425 |
Zuckerman JM, Qamar F, Bono BR. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am 2009;23:997-1026, ix-x. [PMID: 19909895 DOI: 10.1016/j.idc.2009.06.013] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 426 |
Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs. 2013;73:815-824. [PMID: 23625272 DOI: 10.1007/s40265-013-0053-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 427 |
Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209-221. [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 428 |
Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol. 2009;24:1230-1235. [PMID: 19476562 DOI: 10.1111/j.1440-1746.2009.05829.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 429 |
Geng X, Li W, Chen Z, Gao S, Hong W, Ge X, Hou G, Hu Z, Zhou Y, Zeng B, Li W, Jia J, Sun Y. The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. Antimicrob Agents Chemother 2017;61:e02011-16. [PMID: 28242673 DOI: 10.1128/AAC.02011-16] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 430 |
Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40:171-177. [PMID: 24863854 DOI: 10.1111/apt.12808] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 431 |
Lee HJ, Kim JI, Cheung DY, Kim TH, Jun EJ, Oh JH, Chung WC, Kim BW, Kim SS, Park SH. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013;208:1123-1130. [PMID: 23801607 DOI: 10.1093/infdis/jit287] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 432 |
Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am 2011;95:761-91, viii. [PMID: 21679791 DOI: 10.1016/j.mcna.2011.03.012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 433 |
Calik Z, Karamese M, Acar O, Aksak Karamese S, Dicle Y, Albayrak F, Can S, Guvendi B, Turgut A, Cicek M. Investigation of Helicobacter pylori antigen in stool samples of patients with upper gastrointestinal complaints. Braz J Microbiol. 2016;47:167-171. [PMID: 26887240 DOI: 10.1016/j.bjm.2015.11.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 434 |
Holmes KP, Fang JC, Jackson BR. Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. BMC Health Serv Res 2010;10:344. [PMID: 21176158 DOI: 10.1186/1472-6963-10-344] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 435 |
Elseweidy MM, Taha MM, Younis NN, Ibrahim KS, Hamouda HA, Eldosouky MA, Soliman H. Gastritis Induced by Helicobacter pylori Infection in Experimental Rats. Dig Dis Sci 2010;55:2770-7. [DOI: 10.1007/s10620-009-1103-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 436 |
Gorman DF. Towards a sustainable and fit‐for‐purpose health workforce — lessons from New Zealand. Medical Journal of Australia 2013;199. [DOI: 10.5694/mja11.11583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 437 |
Gebeyehu E, Nigatu D, Engidawork E. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A prospective follow up study. PLoS One 2019;14:e0217645. [PMID: 31163069 DOI: 10.1371/journal.pone.0217645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 438 |
Gómez V, Bhalla R, Heckman MG, Florit PT, Diehl NN, Rawal B, Lynch SA, Loeb DS. Routine Screening Endoscopy before Bariatric Surgery: Is It Necessary? Bariatr Surg Pract Patient Care 2014;9:143-9. [PMID: 25516819 DOI: 10.1089/bari.2014.0024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 439 |
Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345-60; quiz 361. [PMID: 22310222 DOI: 10.1038/ajg.2011.480] [Cited by in Crossref: 417] [Cited by in F6Publishing: 301] [Article Influence: 41.7] [Reference Citation Analysis]
|
| 440 |
Wu W, Yang Y, Sun G. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract 2012;2012:723183. [PMID: 22829809 DOI: 10.1155/2012/723183] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 441 |
Gisbert JP, Calvet X. Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. Clin Transl Gastroenterol 2013;4:e32. [PMID: 23535826 DOI: 10.1038/ctg.2013.3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 442 |
Freedberg DE, Abrams JA, Wang TC. Prevention of gastric cancer with antibiotics: can it be done without eradicating Helicobacter pylori? J Natl Cancer Inst 2014;106:dju148. [PMID: 24925352 DOI: 10.1093/jnci/dju148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 443 |
Wong SH, Sung JJ. Management of Patients with Rebleeding. Gastrointest Endosc Clin N Am 2015;25:569-81. [PMID: 26142039 DOI: 10.1016/j.giec.2015.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 444 |
Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 445 |
Lee YC, Tseng PH, Liou JM, Chen MJ, Chen CC, Tu CH, Chiang TH, Chiu HM, Lai CF, Ho JC. Performance of a one-step fecal sample-based test for diagnosis of Helicobacter pylori infection in primary care and mass screening settings. J Formos Med Assoc. 2014;113:899-907. [PMID: 25530066 DOI: 10.1016/j.jfma.2012.05.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 446 |
Kim JS, Jang YR, Lee JW, Kim JY, Jung YK, Chung DH, Kwon OS, Kim YS, Choi DJ, Kim JH. A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage. Korean J Hepatol. 2011;17:229-232. [PMID: 22102391 DOI: 10.3350/kjhep.2011.17.3.229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 447 |
Kim SY, Jung SW. [Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol 2011;58:67-73. [PMID: 21873820 DOI: 10.4166/kjg.2011.58.2.67] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 448 |
Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008;68:725-736. [PMID: 18416582 DOI: 10.2165/00003495-200868060-00001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 449 |
Haider RB, Brennan DE, Omorogbe J, Holleran G, Hall B, O'Morain C, Breslin N, O'Connor HJ, Smith SM, McNamara D. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. Eur J Gastroenterol Hepatol. 2015;27:1265-1269. [PMID: 26287955 DOI: 10.1097/meg.0000000000000457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 450 |
Ferwana M, Abdulmajeed I, Alhajiahmed A, Madani W, Firwana B, Hasan R, Altayar O, Limburg PJ, Murad MH, Knawy B. Accuracy of urea breath test in Helicobacter pylori infection: Meta-analysis. World J Gastroenterol 2015; 21(4): 1305-1314 [PMID: 25632206 DOI: 10.3748/wjg.v21.i4.1305] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 451 |
Figura N, Marcolongo R, Cavallo G, Santucci A, Collodel G, Spreafico A, Moretti E. Polysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural study. BMC Microbiol 2012;12:217. [PMID: 22998649 DOI: 10.1186/1471-2180-12-217] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 452 |
Luther J, Chey WD, Saad RJ. A clinician’s guide to salvage therapy for persistent Helicobacter pylori infection. Hosp Pract (1995). 2011;39:133-140. [PMID: 21441768 DOI: 10.3810/hp.2011.02.383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 453 |
Kato H, Kagami Y, Kodaira T, Oka S, Oki Y, Chihara D, Taji H, Yatabe Y, Nakamura T, Nakamura S, Seto M, Yamamoto K, Morishima Y. Nodal Relapse After Helicobacter pylori Eradication in a Patient With Primary Localized Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. American Journal of Gastroenterology 2011;106:549-51. [DOI: 10.1038/ajg.2010.457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 454 |
Shirin H, Leja M, Niv Y. Helicobacter pylori and Non-malignant Diseases. Helicobacter 2008;13:23-7. [DOI: 10.1111/j.1523-5378.2008.00635.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 455 |
Kwok A, Lam T, Katelaris P, Leong RW. Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin Drug Saf 2008;7:271-81. [PMID: 18462185 DOI: 10.1517/14740338.7.3.271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 456 |
Suzuki H, Matsuzaki J, Hibi T. Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for Helicobacter pylori eradication? Expert Rev Clin Pharmacol 2011;4:579-82. [PMID: 22114887 DOI: 10.1586/ecp.11.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 457 |
Olafsson S, Patel B, Jackson C, Cai J. Helicobacter pylori breath testing in an open access system has a high rate of potentially false negative results due to protocol violations. Helicobacter. 2012;17:391-395. [PMID: 22967123 DOI: 10.1111/j.1523-5378.2012.00964.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 458 |
Chung JW, Lee JH, Jung HY, Yun SC, Oh TH, Choi KD, Song HJ, Lee GH, Kim JH. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter. 2011;16:289-294. [PMID: 21762268 DOI: 10.1111/j.1523-5378.2011.00844.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 459 |
Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Pharmacotherapy. 2015;35:719-730. [PMID: 26173786 DOI: 10.1002/phar.1614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 460 |
Shih HY, Kuo FC, Wang SS, Liu YC, Wu MC, Chang YP, Chiu GF, Chang PY, Wu DC, Hsieh MC, Chen YL. Helicobacter pylori Infection and Anemia in Taiwanese Adults. Gastroenterol Res Pract 2013;2013:390967. [PMID: 24348534 DOI: 10.1155/2013/390967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 461 |
Tonkic A, Vukovic J, Vrebalov Cindro P, Pesutic Pisac V, Tonkic M. Diagnosis of Helicobacter pylori infection : A short review. Wien Klin Wochenschr 2018;130:530-4. [PMID: 29959527 DOI: 10.1007/s00508-018-1356-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 462 |
Batts KP, Ketover S, Kakar S, Krasinskas AM, Mitchell KA, Wilcox R, Westerhoff M, Rank J, Gibson J, Mattia AR, Cummings OW, Davison JM, Naini BV, Dry SM, Yantiss RK; Rodger C Haggitt Gastrointestinal Pathology Society. Appropriate use of special stains for identifying Helicobacter pylori: Recommendations from the Rodger C. Haggitt Gastrointestinal Pathology Society. Am J Surg Pathol 2013;37:e12-22. [PMID: 24141174 DOI: 10.1097/PAS.0000000000000097] [Cited by in Crossref: 59] [Cited by in F6Publishing: 10] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 463 |
Ebrahem R, Kadhem S, Frey JW, Salyers W. Endoscopic View of Gastroduodenal Artery Coils at the Base of Duodenal Ulcer in Case of Recurrent Massive Upper Gastrointestinal Bleed. Cureus 2017;9:e1163. [PMID: 28507835 DOI: 10.7759/cureus.1163] [Reference Citation Analysis]
|
| 464 |
Keller J, Hammer HF, Afolabi PR, Benninga M, Borrelli O, Dominguez-Munoz E, Dumitrascu D, Goetze O, Haas SL, Hauser B, Pohl D, Salvatore S, Sonyi M, Thapar N, Verbeke K, Fox MR; European 13C-breath test group. European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC. United European Gastroenterol J 2021;9:598-625. [PMID: 34128346 DOI: 10.1002/ueg2.12099] [Reference Citation Analysis]
|
| 465 |
Bergogne-bérézin E. Bacteria: Helicobacter pylori. Encyclopedia of Food Safety. Elsevier; 2014. pp. 446-9. [DOI: 10.1016/b978-0-12-378612-8.00100-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 466 |
Toyoshima O, Nishizawa T, Yoshida S, Sakaguchi Y, Nakai Y, Watanabe H, Suzuki H, Tanikawa C, Matsuda K, Koike K. Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity. World J Gastroenterol 2020; 26(34): 5146-5155 [PMID: 32982115 DOI: 10.3748/wjg.v26.i34.5146] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 467 |
Khu JV, Lim LL. Helicobacter pylori Eradication Regimens: Is there a Difference? Journal of Pharmacy Practice and Research 2010;40:194-8. [DOI: 10.1002/j.2055-2335.2010.tb00537.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 468 |
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439-1446. [PMID: 26935876 DOI: 10.1136/gutjnl-2015-311304] [Cited by in Crossref: 160] [Cited by in F6Publishing: 149] [Article Influence: 26.7] [Reference Citation Analysis]
|
| 469 |
Miendje Deyi VY, Van den Borre C, Fontaine V. Comparative evaluation of 3 selective media for primary isolation of Helicobacter pylori from gastric biopsies under routine conditions. Diagn Microbiol Infect Dis. 2010;68:474-476. [PMID: 20926220 DOI: 10.1016/j.diagmicrobio.2010.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 470 |
Hashem-Dabaghian F, Agah S, Taghavi-Shirazi M, Ghobadi A. Combination of Nigella sativa and Honey in Eradication of Gastric Helicobacter pylori Infection. Iran Red Crescent Med J 2016;18:e23771. [PMID: 28191328 DOI: 10.5812/ircmj.23771] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 471 |
Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori: . Current Opinion in Gastroenterology 2011;27:565-70. [DOI: 10.1097/mog.0b013e32834bb818] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 472 |
Talebi Bezmin Abadi A. Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches. J Pathog 2018;2018:9064952. [PMID: 29951318 DOI: 10.1155/2018/9064952] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 473 |
Kim JM, Zheng HM, Lee BY, Lee WK, Lee DH. Anti-Helicobacter pylori Properties of Gut Gard. Prev Nutr Food Sci. 2013;18:104-110. [PMID: 24471118 DOI: 10.3746/pnf.2013.18.2.104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 474 |
Broccoli A, Zinzani PL. How do we sequence therapy for marginal zone lymphomas? Hematology Am Soc Hematol Educ Program 2020;2020:295-305. [PMID: 33275704 DOI: 10.1182/hematology.2020000157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 475 |
Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter. 2013;18:459-467. [PMID: 23714140 DOI: 10.1111/hel.12062] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 476 |
Tabiri S, Akanbong P, Abubakari BB. Assessment of the environmental risk factors for a gastric ulcer in northern Ghana. Pan Afr Med J 2016;25:160. [PMID: 28292122 DOI: 10.11604/pamj.2016.25.160.8531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 477 |
Rozza AL, Hiruma-Lima CA, Tanimoto A, Pellizzon CH. Morphologic and pharmacological investigations in the epicatechin gastroprotective effect. Evid Based Complement Alternat Med 2012;2012:708156. [PMID: 22666296 DOI: 10.1155/2012/708156] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 478 |
Qu XH, Huang XL, Xiong P, Zhu CY, Huang YL, Lu LG, Sun X, Rong L, Zhong L, Sun DY, Lin H, Cai MC, Chen ZW, Hu B, Wu LM, Jiang YB, Yan WL. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010; 16(7): 886-896 [PMID: 20143469 DOI: 10.3748/wjg.v16.i7.886] [Cited by in F6Publishing: 53] [Reference Citation Analysis]
|
| 479 |
Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 480 |
Magsi I, Hussain Keerio S, Kumar C, Talpur AS, Shahzeen F, Mushtaq Abbasi Z, Lohano M, Kumar V, Rizwan A. Response of Helicobacter Pylori Eradication Treatment in Patients With Normal and Below-Normal Serum Vitamin D Levels. Cureus 2021;13:e14777. [PMID: 34094742 DOI: 10.7759/cureus.14777] [Reference Citation Analysis]
|
| 481 |
Jeong HY, Lee TH, Kim JG, Lee S, Moon C, Truong XT, Jeon TI, Moon JH. 3-Pentylcatechol, a Non-Allergenic Urushiol Derivative, Displays Anti-Helicobacter pylori Activity In Vivo. Pharmaceuticals (Basel) 2020;13:E384. [PMID: 33202739 DOI: 10.3390/ph13110384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 482 |
Chien LN, Huang YJ, Shao YH, Chang CJ, Chuang MT, Chiou HY, Yen Y. Proton pump inhibitors and risk of periampullary cancers--A nested case-control study. Int J Cancer. 2016;138:1401-1409. [PMID: 26488896 DOI: 10.1002/ijc.29896] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 483 |
Ryoo SK, Kim TJ, Kim ER, Hong SN, Kim Y, Chang DK. Helicobacter pylori Infection and the Development of Advanced Colorectal Neoplasia. Journal of Clinical Gastroenterology 2020;54:696-700. [DOI: 10.1097/mcg.0000000000001273] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 484 |
Semrau A, Gerold S, Frick JS, Iglauer F. Non-invasive detection and successful treatment of a Helicobacter pylori infection in a captive rhesus macaque. Lab Anim 2017;51:208-11. [PMID: 27609810 DOI: 10.1177/0023677216669179] [Reference Citation Analysis]
|
| 485 |
Yousefi-avarvand A, Vaez H, Tafaghodi M, Sahebkar AH, Arzanlou M, Khademi F. Antibiotic Resistance of Helicobacter pylori in Iranian Children: A Systematic Review and Meta-Analysis. Microbial Drug Resistance 2018;24:980-6. [DOI: 10.1089/mdr.2017.0292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 486 |
Graham DY, Rugge M. Clinical practice: diagnosis and evaluation of dyspepsia. J Clin Gastroenterol. 2010;44:167-172. [PMID: 20009950 DOI: 10.1097/mcg.0b013e3181c64c69] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 487 |
Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Braz J Microbiol 2014;45:1439-48. [PMID: 25763052 DOI: 10.1590/s1517-83822014000400039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 488 |
Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206-214. [PMID: 23241101 DOI: 10.1111/hel.12031] [Cited by in Crossref: 172] [Cited by in F6Publishing: 145] [Article Influence: 17.2] [Reference Citation Analysis]
|
| 489 |
Zhu TT, Wang L, Wang HL, He Y, Ma X, Fan JM. Helicobacter pylori participates in the pathogenesis of IgA nephropathy. Ren Fail 2016;38:1398-404. [PMID: 27764998 DOI: 10.1080/0886022X.2016.1216713] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 490 |
Harmati M, Gyukity-sebestyen E, Dobra G, Terhes G, Urban E, Decsi G, Mimica-dukić N, Lesjak M, Simin N, Pap B, Nemeth IB, Buzas K. Binary mixture of Satureja hortensis and Origanum vulgare subsp. hirtum essential oils: in vivo therapeutic efficiency against Helicobacter pylori infection. Helicobacter 2017;22:e12350. [DOI: 10.1111/hel.12350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 491 |
Cerqueira RM, Manso MC, Correia MR, Fernandes CD, Vilar H, Nora M, Martins P. Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days? Obes Surg. 2011;21:1377-1381. [PMID: 20838918 DOI: 10.1007/s11695-010-0254-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 492 |
Pathak CM, Kaur B, Bhasin DK, Mittal BR, Sharma S, Khanduja KL, Aggarwal L, Rana SS. Comparison of encapsulated versus nonencapsulated (14) C-urea breath test for the detection of Helicobacter pylori infection: a scintigraphy study. Helicobacter. 2014;19:116-123. [PMID: 24237714 DOI: 10.1111/hel.12103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 493 |
Wylie MR, Windham IH, Blum FC, Wu H, Merrell DS. In vitro antibacterial activity of nimbolide against Helicobacter pylori. J Ethnopharmacol 2021;:114828. [PMID: 34763046 DOI: 10.1016/j.jep.2021.114828] [Reference Citation Analysis]
|
| 494 |
Janjetic MA, Goldman CG, Balcarce NE, Rua EC, González AB, Fuda JA, Meseri EI, Torti HE, Barrado J, Zubillaga MB, López LB, Boccio JR. Iron, zinc, and copper nutritional status in children infected with Helicobacter pylori. J Pediatr Gastroenterol Nutr 2010;51:85-9. [PMID: 20410842 DOI: 10.1097/MPG.0b013e3181c2c2cd] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 495 |
El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe SE, Elfant A, Haas T, Hapke RJ, Graham DY. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol 2018;16:992-1002.e6. [PMID: 29559361 DOI: 10.1016/j.cgh.2018.03.013] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 17.8] [Reference Citation Analysis]
|
| 496 |
Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol. 2010;6:29-41. [PMID: 19968574 DOI: 10.1517/17425250903386251] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 497 |
Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-157. [PMID: 23028235 DOI: 10.2147/ceg.s25416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 498 |
Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018;14:111-7. [DOI: 10.1016/j.jgar.2018.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 499 |
Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 500 |
Liou JM, Wu MS, Lin JT. Treatment of Helicobacter pylori infection: Where are we now? J Gastroenterol Hepatol. 2016;31:1918-1926. [PMID: 27088632 DOI: 10.1111/jgh.13418] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 501 |
Dajani AI, Abu Hammour AM, Yang DH, Chung PC, Nounou MA, Yuan KY, Zakaria MA, Schi HS. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? Saudi J Gastroenterol. 2013;19:113-120. [PMID: 23680708 DOI: 10.4103/1319-3767.111953] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 502 |
Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication. World J Gastroenterol 2015; 21(26): 8132-8139 [PMID: 26185386 DOI: 10.3748/wjg.v21.i26.8132] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 503 |
Tang RS, Chan FK. Therapeutic Management of Recurrent Peptic Ulcer Disease: . Drugs 2012;72:1605-16. [DOI: 10.2165/11634850-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 504 |
Paoluzi OA, Visconti E, Andrei F, Tosti C, Lionetti R, Grasso E, Ranaldi R, Stroppa I, Pallone F. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol. 2010;44:261-266. [PMID: 20195162 DOI: 10.1097/mcg.0b013e3181acebef] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 505 |
Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther. 2009;34:41-53. [PMID: 19125902 DOI: 10.1111/j.1365-2710.2008.00969.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 506 |
Fahimi F, Sarhaddi S, Fouladi M, Samadi N, Sadeghi J, Golchin A, Tohidkia MR, Barar J, Omidi Y. Phage display-derived antibody fragments against conserved regions of VacA toxin of Helicobacter pylori. Appl Microbiol Biotechnol 2018;102:6899-913. [PMID: 29862446 DOI: 10.1007/s00253-018-9068-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 507 |
Hwang YJ, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018;47:380-390. [PMID: 29193217 DOI: 10.1111/apt.14424] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 14.8] [Reference Citation Analysis]
|
| 508 |
Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial. Helicobacter 2012;17:458-65. [DOI: 10.1111/j.1523-5378.2012.00971.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 509 |
Nealis TB, Howden CW. Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther. 2008;15:536-542. [PMID: 19127138 DOI: 10.1097/mjt.0b013e31817149bf] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 510 |
Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4:541-548. [PMID: 23929066 DOI: 10.4161/gmic.25930] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 511 |
Khan A, Farooqui A, Manzoor H, Akhtar SS, Quraishy MS, Kazmi SU. Antibiotic resistance and cagA gene correlation: A looming crisis of Helicobacter pylori. World J Gastroenterol 2012; 18(18): 2245-2252 [PMID: 22611319 DOI: 10.3748/wjg.v18.i18.2245] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 512 |
Heineman J, Bubenik S, McClave S, Martindale R. Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? Curr Gastroenterol Rep. 2012;14:343-348. [PMID: 22763792 DOI: 10.1007/s11894-012-0274-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 513 |
Périco LL, Emílio-Silva MT, Ohara R, Rodrigues VP, Bueno G, Barbosa-Filho JM, Rocha LRMD, Batista LM, Hiruma-Lima CA. Systematic Analysis of Monoterpenes: Advances and Challenges in the Treatment of Peptic Ulcer Diseases. Biomolecules 2020;10:E265. [PMID: 32050614 DOI: 10.3390/biom10020265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 514 |
Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011;16:420-426. [PMID: 22059392 DOI: 10.1111/j.1523-5378.2011.00867.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 515 |
Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507-514. [PMID: 21777974 DOI: 10.1016/s0140-6736(11)60825-8] [Cited by in Crossref: 171] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 516 |
Durazzo M, Adriani A, Fagoonee S, Saracco GM, Pellicano R. Helicobacter pylori and Respiratory Diseases: 2021 Update. Microorganisms 2021;9:2033. [PMID: 34683354 DOI: 10.3390/microorganisms9102033] [Reference Citation Analysis]
|
| 517 |
Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014; 20(18): 5252-5262 [PMID: 24833855 DOI: 10.3748/wjg.v20.i18.5252] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 518 |
Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol 2014; 20(36): 12818-12838 [PMID: 25278680 DOI: 10.3748/wjg.v20.i36.12818] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 519 |
Jessee MA. Stool studies: tried, true, and new. Crit Care Nurs Clin North Am 2010;22:129-45. [PMID: 20193887 DOI: 10.1016/j.ccell.2009.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 520 |
Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1-20. [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x] [Cited by in Crossref: 262] [Cited by in F6Publishing: 241] [Article Influence: 21.8] [Reference Citation Analysis]
|
| 521 |
Lash RH, Genta RM. Routine Anti- Helicobacter Immunohistochemical Staining is Significantly Superior to Reflex Staining Protocols for the Detection of Helicobacter in Gastric Biopsy Specimens. Helicobacter 2016;21:581-5. [DOI: 10.1111/hel.12315] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 522 |
Singhi S, Jain P, Jayashree M, Lal S. Approach to a child with upper gastrointestinal bleeding. Indian J Pediatr. 2013;80:326-333. [PMID: 23504479 DOI: 10.1007/s12098-013-0987-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 523 |
Kim JE, Kim MS, Yoon YS, Chung MJ, Yum DY. Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection. J Microbiol. 2014;52:955-962. [PMID: 25277407 DOI: 10.1007/s12275-014-4355-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 524 |
Lee JY, Kim N. Diagnosis of Helicobacter pylori by invasive test: histology. Ann Transl Med. 2015;3:10. [PMID: 25705642 DOI: 10.3978/j.issn.2305-5839.2014.11.03] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
|
| 525 |
Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106:1970-1975. [PMID: 21989146 DOI: 10.1038/ajg.2011.306] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 526 |
Laredo V, Sostres C, Alfaro E, Arroyo MT, Lanas Á. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. Helicobacter 2019;24:e12586. [DOI: 10.1111/hel.12586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 527 |
Shirin D, Matalon S, Avidan B, Broide E, Shirin H. Real-world Helicobacter pylori diagnosis in patients referred for esophagoduodenoscopy: The gap between guidelines and clinical practice. United European Gastroenterol J 2016;4:762-9. [PMID: 28408993 DOI: 10.1177/2050640615626052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 528 |
Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47:233-238. [PMID: 23090037 DOI: 10.1097/mcg.0b013e3182676e2b] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 529 |
Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli Jr J. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011;48:261-264. [PMID: 22147131 DOI: 10.1590/s0004-28032011000400008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 530 |
Girón JA, Shah SL. Helicobacter pylori infection and light chain gammopathy. Clin Dev Immunol 2013;2013:348562. [PMID: 24363759 DOI: 10.1155/2013/348562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 531 |
Cetinkaya ZA, Sezikli M, Güzelbulut F, Coşgun S, Düzgün S, Kurdaş OO. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin. Helicobacter 2010;15:143-7. [PMID: 20402816 DOI: 10.1111/j.1523-5378.2010.00747.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 532 |
Yang JC, Yang YF, Uang YS, Lin CJ, Wang TH. Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol. 2009;67:503-510. [PMID: 19552744 DOI: 10.1111/j.1365-2125.2009.03393.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 533 |
Theel ES, Johnson RD, Plumhoff E, Hanson CA. Use of the Optum Labs Data Warehouse to assess test ordering patterns for diagnosis of Helicobacter pylori infection in the United States. J Clin Microbiol 2015;53:1358-60. [PMID: 25609721 DOI: 10.1128/JCM.03464-14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 534 |
Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;44:427-437. [PMID: 27363687 DOI: 10.1111/apt.13712] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 535 |
Moayyedi P, Malfertheiner P. Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol. 2009;104:3081-3083. [PMID: 19956122 DOI: 10.1038/ajg.2009.563] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 536 |
Al-Badriyeh D, Alabbadi I, Fahey M, Al-Khal A, Zaidan M. Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar. Clin Ther 2016;38:1158-73. [PMID: 27021610 DOI: 10.1016/j.clinthera.2016.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 537 |
Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106-114. [PMID: 28497487 DOI: 10.1111/apt.14130] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 538 |
Shapla UM, Raihan J, Islam A, Alam F, Solayman N, Gan SH, Hossen S, Khalil I. Propolis: The future therapy against Helicobacter pylori-mediated gastrointestinal diseases. J Appl Biomed 2018;16:81-99. [DOI: 10.1016/j.jab.2017.10.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 539 |
Makobongo MO, Gancz H, Carpenter BM, McDaniel DP, Merrell DS. The oligo-acyl lysyl antimicrobial peptide C12K-2β12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob Agents Chemother. 2012;56:378-390. [PMID: 22064541 DOI: 10.1128/aac.00689-11] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 540 |
Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, Song IS. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol 2015; 21(46): 13124-13131 [PMID: 26673999 DOI: 10.3748/wjg.v21.i46.13124] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 541 |
Ali Habib HS, Murad HA, Amir EM, Halawa TF. Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. Indian J Pharmacol. 2013;45:470-473. [PMID: 24130381 DOI: 10.4103/0253-7613.117757] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 542 |
Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: Prevention, screening and early diagnosis. World J Gastroenterol 2014; 20(38): 13842-13862 [PMID: 25320521 DOI: 10.3748/wjg.v20.i38.13842] [Cited by in CrossRef: 153] [Cited by in F6Publishing: 145] [Article Influence: 19.1] [Reference Citation Analysis]
|
| 543 |
Zevit N, Niv Y, Shirin H, Shamir R. Age and gender differences in urea breath test results. Eur J Clin Invest 2011;41:767-72. [PMID: 21261618 DOI: 10.1111/j.1365-2362.2010.02467.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 544 |
Yoon H, Kim N, Lee HS, Shin CM, Park YS, Lee DH, Jung HC, Song IS. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter. 2011;16:382-388. [PMID: 21923684 DOI: 10.1111/j.1523-5378.2011.00859.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 545 |
Qian J, Ye F, Zhang J, Yang YM, Tu HM, Jiang Q, Shang L, Pan XL, Shi RH, Zhang GX. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter. 2012;17:478-485. [PMID: 23067317 DOI: 10.1111/j.1523-5378.2012.00993.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 546 |
Kwon YJ, Kim N, Baek SM, Lee HS, Lee J, Hwang YJ, Yoon H, Shin CM, Park YS, Kim J, Lee DH. The prevalence of histologic atrophy and intestinal metaplasia in the corpus has decreased over 15 years in females in the Korean population. Helicobacter 2019;24:e12579. [DOI: 10.1111/hel.12579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 547 |
El Shahawy MS, Hemida MH, El Metwaly I, Shady ZM. The effect of vitamin D deficiency on eradication rates of Helicobacter pylori infection. JGH Open 2018;2:270-5. [PMID: 30619936 DOI: 10.1002/jgh3.12081] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 548 |
Kim JS, Kim BW, Hong SJ, Kim JI, Shim KN, Kim JH, Baik GH, Kim SW, Song HJ, Kim JH. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. Gut Liver. 2016; Apr 28. [Epub ahead of print]. [PMID: 27114421 DOI: 10.5009/gnl15470] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 549 |
Marin AC, Nyssen OP, Mcnicholl AG, Gisbert JP. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs 2017;77:765-76. [DOI: 10.1007/s40265-017-0730-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 550 |
Hu Q, Zhang Y, Zhang X, Fu K. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomark Res. 2016;4:15. [PMID: 27468353 DOI: 10.1186/s40364-016-0068-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 551 |
Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, Wu O. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol. 2016;16:80. [PMID: 27460211 DOI: 10.1186/s12876-016-0491-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 552 |
Kusunoki H, Kusaka M, Kido S, Yamauchi R, Fujimura Y, Watanabe Y, Kobori M, Miwa H, Tomita T, Kin Y. Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. J Gastroenterol. 2009;44:261-270. [PMID: 19280112 DOI: 10.1007/s00535-009-0003-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 553 |
Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ, Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2016;65:1784-92. [PMID: 26338825 DOI: 10.1136/gutjnl-2015-310142] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 554 |
Sanches BS, Martins GM, Lima K, Cota B, Moretzsohn LD, Ribeiro LT, Breyer HP, Maguilnik I, Maia AB, Rezende-Filho J, Meira AC, Pinto H, Alves E, Mascarenhas R, Passos R, de Souza JD, Trindade OR, Coelho LG. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. World J Gastroenterol 2016; 22(33): 7587-7594 [PMID: 27672279 DOI: 10.3748/wjg.v22.i33.7587] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 555 |
Syam AF, Miftahussurur M, Uwan WB, Simanjuntak D, Uchida T, Yamaoka Y. Validation of Urine Test for Detection of Helicobacter pylori Infection in Indonesian Population. Biomed Res Int. 2015;2015:152823. [PMID: 26824034 DOI: 10.1155/2015/152823] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 556 |
Wang L, Lin Z, Chen S, Li J, Chen C, Huang Z, Ye B, Ding J, Li W, Wu L, Jiang Y, Meng L, Du Q, Si J. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori –related chronic gastritis: a prospective randomized study in China. Clinical Microbiology and Infection 2017;23:391-5. [DOI: 10.1016/j.cmi.2016.12.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 557 |
Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clinical Therapeutics 2010;32:667-77. [DOI: 10.1016/j.clinthera.2010.04.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 558 |
Pinazo MJ, Cañas E, Elizalde JI, García M, Gascón J, Gimeno F, Gomez J, Guhl F, Ortiz V, Posada EDJ, Puente S, Rezende J, Salas J, Saravia J, Torrico F, Torrus D, Treviño B. Diagnosis, management and treatment of chronic Chagas’ gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterología y Hepatología 2010;33:191-200. [DOI: 10.1016/j.gastrohep.2009.07.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 559 |
Kobayashi T, Glatz M, Horiuchi K, Kawasaki H, Akiyama H, Kaplan DH, Kong HH, Amagai M, Nagao K. Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis. Immunity 2015;42:756-66. [PMID: 25902485 DOI: 10.1016/j.immuni.2015.03.014] [Cited by in Crossref: 258] [Cited by in F6Publishing: 224] [Article Influence: 36.9] [Reference Citation Analysis]
|
| 560 |
Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut. 2018;67:20-27. [PMID: 27670375 DOI: 10.1136/gutjnl-2016-311868] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 561 |
Hung H, Chen T, Lin H. Immunoglobulin G Antibody Against Helicobacter pylori Is an Accurate Test for Atrophic Gastritis. Journal of the Chinese Medical Association 2010;73:355-9. [DOI: 10.1016/s1726-4901(10)70077-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 562 |
Bourne C, Charpiat B, Charhon N, Bertin C, Gouraud A, Mouchoux C, Skalli S, Janoly-dumenil A. Effets indésirables émergents des inhibiteurs de la pompe à protons. La Presse Médicale 2013;42:e53-62. [DOI: 10.1016/j.lpm.2012.09.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 563 |
Saad RJ, Chey WD. Breath tests for gastrointestinal disease: the real deal or just a lot of hot air? Gastroenterology 2007;133:1763-6. [PMID: 18054546 DOI: 10.1053/j.gastro.2007.10.059] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 564 |
Schmiloviz-weiss H, Shalev T, Chechoulin Y, Levi Z, Yishai R, Sehayek-shabbat V, Niv Y, Shirin H. High Eradication Rates of Helicobacter pylori Infection Following Sequential Therapy: The Israeli Experience Treating Naïve Patients: Sequential Therapy Eradication Rates Israel. Helicobacter 2011;16:229-33. [DOI: 10.1111/j.1523-5378.2011.00834.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 565 |
Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol 2015; 21(45): 12954-12962 [PMID: 26668516 DOI: 10.3748/wjg.v21.i45.12954] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 566 |
Saad RJ, Chey WD. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy—What's Next? Clinical Gastroenterology and Hepatology 2008;6:1086-90. [DOI: 10.1016/j.cgh.2008.05.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 567 |
Liu XZ, Zhang YM, Jia NY, Zhang H. Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy. Ren Fail 2020;42:539-46. [PMID: 32524871 DOI: 10.1080/0886022X.2020.1772295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 568 |
Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Antimicrob Agents Chemother 2017;61:e00140-17. [PMID: 28807915 DOI: 10.1128/AAC.00140-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 569 |
Ayala G, Escobedo-Hinojosa WI, Cruz-Herrera CFL, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20(6): 1450-1469 [PMID: 24587621 DOI: 10.3748/wjg.v20.i6.1450] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 64] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 570 |
Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. European Journal of Internal Medicine 2010;21:310-4. [DOI: 10.1016/j.ejim.2010.05.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 571 |
Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013;36:340-74. [PMID: 23601856 DOI: 10.1016/j.gastrohep.2013.01.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 572 |
Willems P, de Repentigny J, Hassan GM, Sidani S, Soucy G, Bouin M. The Prevalence of Helicobacter pylori Infection in a Quaternary Hospital in Canada. J Clin Med Res 2020;12:687-92. [PMID: 33224369 DOI: 10.14740/jocmr4348] [Reference Citation Analysis]
|
| 573 |
Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC. Application of liposomes in drug development--focus on gastroenterological targets. Int J Nanomedicine. 2013;8:1325-1334. [PMID: 23630417 DOI: 10.2147/ijn.s42153] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 574 |
Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012;2012:168361. [PMID: 22792095 DOI: 10.1155/2012/168361] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 575 |
Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118. [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671.x] [Cited by in Crossref: 151] [Cited by in F6Publishing: 153] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 576 |
Ali E, Arshad N, Bukhari NI, Nawaz Tahir M, Zafar S, Hussain A, Parveen S, Qamar S, Shehzadi N, Hussain K. Linking traditional anti-ulcer use of rhizomes of Bergenia ciliata (Haw.) to its anti-Helicobacter pylori constituents. Nat Prod Res 2020;34:541-4. [PMID: 30362366 DOI: 10.1080/14786419.2018.1488711] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 577 |
Nayar DS. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. Infect Drug Resist 2018;11:205-11. [PMID: 29430191 DOI: 10.2147/IDR.S153617] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 578 |
Buzás GM. Fate of meta-analyses: The case of Helicobacter pylori. World J Meta-Anal 2015; 3(1): 20-25 [DOI: 10.13105/wjma.v3.i1.20] [Reference Citation Analysis]
|
| 579 |
Oxentenko AS, Bundrick JB, Litin SC. Clinical pearls in gastroenterology 2011. Mayo Clin Proc 2011;86:1104-8. [PMID: 22033255 DOI: 10.4065/mcp.2011.0399] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 580 |
dos Santos AA, Carvalho AA. Pharmacological therapy used in the elimination of Helicobacter pylori infection: A review. World J Gastroenterol 2015; 21(1): 139-154 [PMID: 25574087 DOI: 10.3748/wjg.v21.i1.139] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 581 |
Mukherjee S, Jana T, Pan JJ. Adverse Effects of Proton Pump Inhibitors on Platelet Count: A Case Report and Review of the Literature. Case Rep Gastrointest Med 2018;2018:4294805. [PMID: 29854491 DOI: 10.1155/2018/4294805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 582 |
Mcnicholl AG, O’morain CA, Megraud F, Gisbert JP; As Scientific Committee of the Hp‐Eureg on Behalf of the National Coordinators. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg). Helicobacter 2019;24. [DOI: 10.1111/hel.12630] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 583 |
Kwon TJ, Kim TJ, Lee H, Min YW, Min BH, Lee JH, Kim JJ. Statin Use Decreases the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection. Cancers (Basel) 2021;13:1020. [PMID: 33804425 DOI: 10.3390/cancers13051020] [Reference Citation Analysis]
|
| 584 |
Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. Korean J Gastroenterol. 2009;54:269-278. [PMID: 19934608 DOI: 10.4166/kjg.2009.54.5.269] [Cited by in Crossref: 99] [Cited by in F6Publishing: 82] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 585 |
Calvet X. What is the best first-line therapy for Helicobacter pylori infection? Nat Rev Gastroenterol Hepatol 2008;5:606-7. [DOI: 10.1038/ncpgasthep1252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 586 |
Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:25-32. [PMID: 23090045 DOI: 10.1097/mcg.0b013e318266f6cf] [Cited by in Crossref: 94] [Cited by in F6Publishing: 49] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 587 |
Syam AF, Miftahussurur M, Makmun D, Nusi IA, Zain LH, Zulkhairi , Akil F, Uswan WB, Simanjuntak D, Uchida T. Risk Factors and Prevalence of Helicobacter pylori in Five Largest Islands of Indonesia: A Preliminary Study. PLoS One. 2015;10:e0140186. [PMID: 26599790 DOI: 10.1371/journal.pone.0140186] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 588 |
Son JH, Lebwohl B, Sepulveda AR, Lagana SM. Utilization Rate of Helicobacter pylori Immunohistochemistry Is Not Associated With the Diagnostic Rate of Helicobacter pylori Infection. Appl Immunohistochem Mol Morphol 2019;27:694-8. [PMID: 30499817 DOI: 10.1097/PAI.0000000000000680] [Reference Citation Analysis]
|
| 589 |
Sanches B, Coelho L, Moretzsohn L, Vieira G. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter. 2008;13:572-576. [PMID: 19166424 DOI: 10.1111/j.1523-5378.2008.00649.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 590 |
Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 591 |
Trung TT, Minh TA, Anh NT. Value of CIM, CLO Test and Multiplex PCR for the Diagnosis of Helicobacter Pylori Infection Status in Patients with Gastritis and Gastric Ulcer. Asian Pac J Cancer Prev 2019;20:3497-503. [PMID: 31759377 DOI: 10.31557/APJCP.2019.20.11.3497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 592 |
Pilotto A, Franceschi M, Maggi S, Addante F, Sancarlo D. Optimal management of peptic ulcer disease in the elderly. Drugs Aging. 2010;27:545-558. [PMID: 20583849 DOI: 10.2165/11537380-000000000-00000] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 593 |
Hasni S, Ippolito A, Illei GG. Helicobacter pylori and autoimmune diseases. Oral Dis. 2011;17:621-627. [PMID: 21902767 DOI: 10.1111/j.1601-0825.2011.01796.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 594 |
Panarese A, Galatola G, Armentano R, Pimentel-Nunes P, Ierardi E, Caruso ML, Pesce F, Lenti MV, Palmitessa V, Coletta S, Shahini E. Helicobacter pylori-induced inflammation masks the underlying presence of low-grade dysplasia on gastric lesions. World J Gastroenterol 2020; 26(26): 3834-3850 [PMID: 32774061 DOI: 10.3748/wjg.v26.i26.3834] [Reference Citation Analysis]
|
| 595 |
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212-239. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 515] [Cited by in F6Publishing: 415] [Article Influence: 103.0] [Reference Citation Analysis]
|
| 596 |
O'connor A, Gisbert J, O’morain C. Treatment of Helicobacter pylori Infection. Helicobacter 2009;14:46-51. [DOI: 10.1111/j.1523-5378.2009.00704.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 597 |
Epstein A, Wing DA, Ouzounian JG, Miller DA, Lee RH. Helicobacter pylori and thrombocytopenia in the pregnant hispanic population. The Journal of Maternal-Fetal & Neonatal Medicine 2012;25:2588-90. [DOI: 10.3109/14767058.2012.713054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 598 |
Oppong P, Majumdar D, Atherton J, Bebb J. Helicobacter pylori infection and peptic ulcers. Medicine 2015;43:215-22. [DOI: 10.1016/j.mpmed.2015.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 599 |
Karczewska E, Klesiewicz K, Skiba I, Wojtas-bonior I, Sito E, Czajecki K, Zwolińska-wcisło M, Budak A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterology Research and Practice 2012;2012:1-7. [DOI: 10.1155/2012/418010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 600 |
Ibrahim N, El Said H, Choukair A. Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study. World J Clin Cases 2022; 10(1): 227-235 [DOI: 10.12998/wjcc.v10.i1.227] [Reference Citation Analysis]
|
| 601 |
Gurusamy KS, Yaghoobi M, Davidson BR; Cochrane Upper GI and Pancreatic Diseases Group. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012080] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 602 |
Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, Miwa H, Lim KJ, Das KM. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol 2014; 20(18): 5461-5473 [PMID: 24833876 DOI: 10.3748/wjg.v20.i18.5461] [Cited by in CrossRef: 103] [Cited by in F6Publishing: 90] [Article Influence: 12.9] [Reference Citation Analysis]
|
| 603 |
Malfertheiner P, Bazzoli F, Delchier J, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet 2011;377:905-13. [DOI: 10.1016/s0140-6736(11)60020-2] [Cited by in Crossref: 310] [Cited by in F6Publishing: 117] [Article Influence: 28.2] [Reference Citation Analysis]
|
| 604 |
Malnick SDH, Melzer E, Attali M, Duek G, Yahav J. Helicobacter pylori: Friend or foe? World J Gastroenterol 2014; 20(27): 8979-8985 [PMID: 25083071 DOI: 10.3748/wjg.v20.i27.8979] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
|
| 605 |
Negash M, Kassu A, Amare B, Yismaw G, Moges B. Evaluation of SD BIOLINE H. pylori Ag rapid test against double ELISA with SD H. pylori Ag ELISA and EZ-STEP H. pylori Ag ELISA tests. BMC Clin Pathol 2018;18:4. [PMID: 29515332 DOI: 10.1186/s12907-018-0071-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 606 |
Molina-infante J, Pazos-pacheco C, Vinagre-rodriguez G, Perez-gallardo B, Dueñas-sadornil C, Hernandez-alonso M, Gonzalez-garcia G, Mateos-rodriguez JM, Fernandez-bermejo M, Gisbert JP. Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains: Nonbismuth Quadruple Concomitant Therapy for Helicobacter pylori infection. Helicobacter 2012;17:269-76. [DOI: 10.1111/j.1523-5378.2012.00947.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 607 |
Liou JM, Bair MJ, Chen CC, Lee YC, Chen MJ, Chen CC, Tseng CH, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Chang WH, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hung HW, Lin JT, Chang CY, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial. Am J Gastroenterol. 2016;111:381-387. [PMID: 26832653 DOI: 10.1038/ajg.2015.439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 608 |
Kwon JH, Lee DH, Song BJ, Lee JW, Kim JJ, Park YS, Kim N, Jeong SH, Kim JW, Lee SH. Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study. Helicobacter. 2010;15:148-153. [PMID: 20402817 DOI: 10.1111/j.1523-5378.2010.00748.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 609 |
Park JB, Koo JS. Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2014; 20(11): 2751-2759 [PMID: 24659867 DOI: 10.3748/wjg.v20.i11.2751] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 610 |
Marsicano E, Vuong GM, Prather CM. Gastrointestinal causes of abdominal pain. Obstet Gynecol Clin North Am 2014;41:465-89. [PMID: 25155126 DOI: 10.1016/j.ogc.2014.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 611 |
Chung JW, Jung YK, Kim YJ, Kwon KA, Kim JH, Lee JJ, Lee SM, Hahm KB, Lee SM, Jeong JY, Yun SC. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012;27:1675-80. [PMID: 22849546 DOI: 10.1111/j.1440-1746.2012.07249.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 612 |
Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 2013;309:578-86. [PMID: 23403682 DOI: 10.1001/jama.2013.311] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 613 |
Wu MC, Huang CY, Kuo FC, Hsu WH, Wang SS, Shih HY, Liu CJ, Chen YH, Wu DC, Huang YL, Lu CY. The effect of Helicobacter pylori eradication on the levels of essential trace elements. Biomed Res Int 2014;2014:513725. [PMID: 25548772 DOI: 10.1155/2014/513725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 614 |
Iwamoto A, Tanahashi T, Okada R, Yoshida Y, Kikuchi K, Keida Y, Murakami Y, Yang L, Yamamoto K, Nishiumi S, Yoshida M, Azuma T. Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes. Gut Pathog. 2014;6:27. [PMID: 24995043 DOI: 10.1186/1757-4749-6-27] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 615 |
Abadi ATB. Strategies used by helicobacter pylori to establish persistent infection. World J Gastroenterol 2017; 23(16): 2870-2882 [PMID: 28522905 DOI: 10.3748/wjg.v23.i16.2870] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 616 |
Leow AH, Azmi AN, Loke M, Vadivelu J, Graham DY, Goh K. Optimizing first line 7‐day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis 2018;19:674-7. [DOI: 10.1111/1751-2980.12679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 617 |
Can ME, Kaplan FE, Uzel MM, Kiziltoprak H, Ergun MC, Koc M, Simsek G. The association of Helicobacter pylori with choroidal and retinal nerve fiber layer thickness. Int Ophthalmol 2018;38:1915-22. [PMID: 28780617 DOI: 10.1007/s10792-017-0677-1] [Reference Citation Analysis]
|
| 618 |
Zhou L, Zhang J, Chen M, Hou X, Li Z, Song Z, He L, Lin S. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol. 2014;109:535-541. [PMID: 24642580 DOI: 10.1038/ajg.2014.26] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 619 |
Wu Y, Zheng Q, Xu Y, Chu W, Cui Y, Wang Y, Zhang H. Insight into the urea binding and K166R mutation stabilizing mechanism of TlpB: Molecular dynamics and principal component analysis study. Chem Res Chin Univ 2014;30:1011-7. [DOI: 10.1007/s40242-014-4135-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 620 |
Shahrashoob M, Mohsenifar A, Tabatabaei M, Rahmani-cherati T, Mobaraki M, Mota A, Shojaei TR. Detection of Helicobacter Pylori Genome with an Optical Biosensor Based on Hybridization of Urease Gene with a Gold Nanoparticles-Labeled Probe. J Appl Spectrosc 2016;83:322-9. [DOI: 10.1007/s10812-016-0290-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 621 |
Abuhammour A, Dajani A, Nounou M, Zakaria M. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. Arab J Gastroenterol 2016;17:131-6. [PMID: 27665525 DOI: 10.1016/j.ajg.2016.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 622 |
Zhang G, Zou J, Liu F, Bao Z, Dong F, Huang Y, Yin S. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res. 2013;46:607-613. [PMID: 23903685 DOI: 10.1590/1414-431x20132817] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 623 |
Pan-in P, Tachapruetinun A, Chaichanawongsaroj N, Banlunara W, Suksamrarn S, Wanichwecharungruang S. Combating Helicobacter pylori infections with mucoadhesive nanoparticles loaded with Garcinia mangostana extract. Nanomedicine 2014;9:457-68. [DOI: 10.2217/nnm.13.30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 624 |
Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931-950. [PMID: 21365243 DOI: 10.1007/s10620-010-1560-3] [Cited by in Crossref: 187] [Cited by in F6Publishing: 167] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 625 |
Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication: . European Journal of Gastroenterology & Hepatology 2016;28:676-83. [DOI: 10.1097/meg.0000000000000590] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 626 |
Vilaichone RK, Yamaoka Y, Shiota S, Ratanachu-ek T, Tshering L, Uchida T, Fujioka T, Mahachai V. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol 2013; 19(33): 5508-5512 [PMID: 24023494 DOI: 10.3748/wjg.v19.i33.5508] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 627 |
de Leest HT, Steen KS, Lems WF, van de Laar MA, Huisman AM, Kadir SW, Houben HH, Kostense PJ, Kuipers EJ, Dijkmans BA, Debets-Ossenkopp YJ. Efficacy of serology driven "test and treat strategy" for eradication of H. pylori in patients with rheumatic disease in the Netherlands. Eur J Clin Microbiol Infect Dis 2011;30:903-8. [PMID: 21293900 DOI: 10.1007/s10096-011-1174-5] [Reference Citation Analysis]
|
| 628 |
Panarelli NC, Ross DS, Bernheim OE, Landzberg ZB, Schuetz AN, Jenkins SG, Landzberg BR, Jessurun J, Yantiss RK. Utility of ancillary stains for Helicobacter pylori in near-normal gastric biopsies. Human Pathology 2015;46:397-403. [DOI: 10.1016/j.humpath.2014.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 629 |
Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. Helicobacter. 2012;17:49-53. [PMID: 22221616 DOI: 10.1111/j.1523-5378.2011.00911.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 630 |
Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17(35): 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 631 |
Wong F, Ou G, Svarta S, Kwok R, Donaldson K, Frenette J, Enns R. Do we eradicate Helicobacter pylori in hospitalized patients with peptic ulcer disease? Can J Gastroenterol 2013;27:636-8. [PMID: 24040632 DOI: 10.1155/2013/249562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 632 |
Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010;122:413-422. [PMID: 20628905 DOI: 10.1007/s00508-010-1404-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 633 |
Nagaraja V, Eslick GD. Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: A systematic review. World J Gastroenterol 2014; 20(40): 14527-14536 [PMID: 25356018 DOI: 10.3748/wjg.v20.i40.14527] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 634 |
Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ, Moons V, Van Olmen G, Smismans A, Bourgain C, Bossuyt P, Frans J. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay. Acta Clin Belg 2021;76:177-83. [PMID: 31662122 DOI: 10.1080/17843286.2019.1685741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 635 |
Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015;13:1616-1624. [PMID: 25681693 DOI: 10.1016/j.cgh.2015.02.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 636 |
O'Connor JP, Taneike I, O'Morain C. Improving compliance with helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2:273-279. [PMID: 21180555 DOI: 10.1177/1756283x09337342] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 637 |
Nelson A, Bi Y, Harris D. Helicobacter Pylori: a comprehensive review for primary care providers. Rom J Intern Med 2021;59:112-8. [PMID: 33565305 DOI: 10.2478/rjim-2020-0043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 638 |
Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One. 2014;9:e85620. [PMID: 24465624 DOI: 10.1371/journal.pone.0085620] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 639 |
Vakil N. Editorial: H. pylori Treatment: New Wine in Old Bottles? Am J Gastroenterol 2009;104:26-30. [DOI: 10.1038/ajg.2008.91] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 640 |
Lopetuso LR, Napoli M, Rizzatti G, Scaldaferri F, Franceschi F, Gasbarrini A. Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2018;12:899-906. [PMID: 30040500 DOI: 10.1080/17474124.2018.1503946] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 641 |
Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, Kim JW, Hwang JH, Park YS, Lee SH. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol. 2012;27:504-509. [PMID: 21916989 DOI: 10.1111/j.1440-1746.2011.06922.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 642 |
Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT, Kim JB, Kim DJ, Kim JB, Shin WG, Kim HY, Baik IH, Jang HJ. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012; 18(45): 6628-6634 [PMID: 23236238 DOI: 10.3748/wjg.v18.i45.6628] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 643 |
Albrecht P, Kotowska M, Szajewska H. Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial. J Pediatr. 2011;159:45-49. [PMID: 21371717 DOI: 10.1016/j.jpeds.2011.01.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 644 |
Evans G, Barker A, Simon L, Kushnir V. High Cost for Low Yield: A Systematic Review and Meta-Analysis to Assess Cost of Routine Preoperative Esophagogastroduodenoscopy Before Bariatric Surgery. J Clin Gastroenterol 2020;54:398-404. [PMID: 32168132 DOI: 10.1097/MCG.0000000000001334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 645 |
Szadkowski A, Zemlak M, Muszyński J. Effectiveness of Helicobacter pylori eradication established on the basis of examination of antibiotic resistance of the bacteria. Prz Gastroenterol 2018;13:93-8. [PMID: 30002766 DOI: 10.5114/pg.2018.75821] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 646 |
Yogeswaran K, Chen G, Cohen L, Cooper MA, Yong E, Hsieh E, Rowsell C, Saibil F, Tinmouth J. How well is Helicobacter pylori treated in usual practice? Can J Gastroenterol 2011;25:543-6. [PMID: 22059158 DOI: 10.1155/2011/647904] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 647 |
Chuah SK, Liang CM, Lee CH, Chiou SS, Chiu YC, Hu ML, Wu KL, Lu LS, Chou YP, Chang KC, Kuo CH, Kuo CM, Hu TH, Tai WC. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication. Medicine (Baltimore) 2016;95:e3586. [PMID: 27175657 DOI: 10.1097/MD.0000000000003586] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 648 |
Triadafilopoulos G, Roorda AK, Akiyama J. Indications and safety of proton pump inhibitor drug use in patients with cancer. Expert Opin Drug Saf. 2013;12:659-672. [PMID: 23647006 DOI: 10.1517/14740338.2013.797961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 649 |
Suzuki RB, Almeida CM, Sperança MA. Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol 2012;12:49. [PMID: 22594560 DOI: 10.1186/1471-230X-12-49] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 650 |
Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: When and How to Test for Helicobacter pylori Infection. Gastroenterol Res Pract 2016;2016:8463614. [PMID: 27239194 DOI: 10.1155/2016/8463614] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 651 |
Dorer MS, Fero J, Salama NR. DNA damage triggers genetic exchange in Helicobacter pylori. PLoS Pathog 2010;6:e1001026. [PMID: 20686662 DOI: 10.1371/journal.ppat.1001026] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 652 |
Jin X, Chen YP, Chen SH, Xiang Z. Association between Helicobacter Pylori infection and ulcerative colitis--a case control study from China. Int J Med Sci. 2013;10:1479-1484. [PMID: 24046521 DOI: 10.7150/ijms.6934] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 653 |
Kim JJ, Lee JS, Olafsson S, Laine L. Low adherence to Helicobacter pylori testing in hospitalized patients with bleeding peptic ulcer disease. Helicobacter. 2014;19:98-104. [PMID: 24617668 DOI: 10.1111/hel.12114] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 654 |
Hussain A, Tabrez E, Peela J, Honnavar P Dr, Tabrez SSM. Vitamin C: A Preventative, Therapeutic Agent Against Helicobacter pylori. Cureus 2018;10:e3062. [PMID: 30280058 DOI: 10.7759/cureus.3062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 655 |
Agréus L, Talley NJ, Jones M. Value of the “Test & Treat” Strategy for Uninvestigated Dyspepsia at Low Prevalence Rates of Helicobacter pylori in the Population. Helicobacter 2016;21:186-91. [DOI: 10.1111/hel.12267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 656 |
Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 124] [Article Influence: 11.1] [Reference Citation Analysis]
|
| 657 |
Hung IF, Wong BC. Assessing the risks and benefits of treating Helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:141-147. [PMID: 21180540 DOI: 10.1177/1756283x08100279] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 658 |
Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069-1079. [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 105] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 659 |
Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol. 2011;4:103-114. [PMID: 21694812 DOI: 10.1177/1756283x10384171] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 660 |
Cryer B. Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterol Clin North Am. 2009;38:289-303. [PMID: 19446259 DOI: 10.1016/j.gtc.2009.03.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 661 |
Tatemichi M, Iwasaki M, Sasazuki S, Tsugane S. Association between polymorphisms in glutathione S-transferase Mu3 and IgG titer levels in serum against Helicobacter pylori. J Hum Genet 2009;54:557-63. [DOI: 10.1038/jhg.2009.77] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 662 |
Deng B, Li Y, Zhang Y, Bai L, Yang P. Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis. Carcinogenesis. 2013;34:1189-1195. [PMID: 23568955 DOI: 10.1093/carcin/bgt114] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 663 |
Kim PK, Dorshimer GW. Case report: peptic ulcer disease in a professional athlete. Phys Sportsmed 2009;37:136-40. [PMID: 20048520 DOI: 10.3810/psm.2009.06.1720] [Reference Citation Analysis]
|
| 664 |
Yilmaz O. Progress in developing accurate tests for the diagnosis of Helicobacter pylori infection. Expert Opin Med Diagn 2007;1:531-40. [PMID: 23496359 DOI: 10.1517/17530059.1.4.531] [Reference Citation Analysis]
|
| 665 |
Chung KT, Shelat VG. Perforated peptic ulcer - an update. World J Gastrointest Surg 2017; 9(1): 1-12 [PMID: 28138363 DOI: 10.4240/wjgs.v9.i1.1] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 47] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 666 |
Gisbert JP, Calvet X. Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther. 2011;34:1047-1062. [PMID: 21919927 DOI: 10.1111/j.1365-2036.2011.04839.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 667 |
Yang GH, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Gastric Helicobacter pylori infection associated with risk of diabetes mellitus, but not prediabetes. J Gastroenterol Hepatol. 2014;29:1794-1799. [PMID: 24731067 DOI: 10.1111/jgh.12617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 668 |
Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111:949-956. [PMID: 27185079 DOI: 10.1038/ajg.2016.182] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 669 |
Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol. 2010;26:618-623. [PMID: 20827182 DOI: 10.1097/mog.0b013e32833efede] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 670 |
Abu-Sini M, Mayyas A, Al-Karablieh N, Darwish R, Al-Hiari Y, Aburjai T, Arabiyat S, Abu-Qatouseh L. Synthesis of 1,2,3-Triazolo[4,5-h]quinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant Helicobacter pylori. Molecules 2017;22:E841. [PMID: 28531095 DOI: 10.3390/molecules22050841] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 671 |
Puram S, Suh HC, Kim SU, Bethapudi B, Joseph JA, Agarwal A, Kudiganti V. Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study. Evid Based Complement Alternat Med. 2013;2013:263805. [PMID: 23606875 DOI: 10.1155/2013/263805] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 672 |
Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A, González-Colominas E, Aresti-Zárate S. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother. 2012;67:2254-2259. [PMID: 22687889 DOI: 10.1093/jac/dks209] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 673 |
Yoon H. Levofloxacin or Rifabutin-Based Triple Therapy. In: Kim N, editor. Helicobacter pylori. Singapore: Springer; 2016. pp. 473-8. [DOI: 10.1007/978-981-287-706-2_46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 674 |
Uguen A. Detection of Helicobacter pylori in virtual slides requires high resolution digitalisation. J Clin Pathol 2021:jclinpath-2020-207378. [PMID: 33568425 DOI: 10.1136/jclinpath-2020-207378] [Reference Citation Analysis]
|
| 675 |
Jodlowski TZ, Lam S, Ashby CR. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother. 2008;42:1621-1639. [PMID: 18845620 DOI: 10.1345/aph.1l234] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 676 |
Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2013;68:450-456. [PMID: 23099849 DOI: 10.1093/jac/dks407] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 677 |
Nekhai S, Gordeuk VR. Iron Metabolism in Cancer and Infection. In: Anderson GJ, Mclaren GD, editors. Iron Physiology and Pathophysiology in Humans. Totowa: Humana Press; 2012. pp. 477-95. [DOI: 10.1007/978-1-60327-485-2_24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [ |
